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Summary 
The glycoprotein 130 (gp130) is the signal transducing element common to all interleukin 
(IL)-6 type cytokines. Signals mediated by gp130 are involved in several biological processes 
such as hematopoiesis, cell differentiation and immune reactions. To initiate downstream 
signaling, a complex of gp130 and the ligand-specific α-receptor chain needs to be formed. 
Pathways activated by gp130-mediated signaling include the Janus kinase/signal transducer 
and activator of transcription (JAK/STAT) and the Src homology 2-domain containing 
tyrosine phosphatase/extracellular signal-regulated kinase (SHP2/ERK) cascade.  
While gp130 is found on most cells, expression of ligand-binding receptor chains is restricted 
to particular cell types. It has therefore long been assumed that the expression pattern of 
α-receptors determines the sensitivity of cells to IL-6 type cytokines. However, depending on 
the regulatory state of a cell, expression of gp130 may vary and thus alter responsiveness. 
The importance of strictly regulated gp130 surface expression is further underlined by the 
fact that the soluble α-receptor of IL-6, sIL-6R, can replace the membrane-bound receptor 
and induce signaling in cells expressing only gp130. 
In hepatocytes, a rapid downregulation of gp130 surface expression by pro-inflammatory 
cytokines has been described. This downregulation was mediated by the stress-induced 
mitogen-activated protein kinase (MAPK) p38, phosphorylation of serine 782 within the 
cytoplasmic tail of gp130 and its subsequent internalization and degradation. The reduced 
availability of the receptor on the cell surface restricted IL-6-induced STAT3 activation. Since 
IL-6 plays an important role in several immune reactions, we asked whether this regulatory 
mechanism might be of relevance in human monocytes. Different approaches confirmed that 
gp130 was internalized in response to the pro-inflammatory stimulus IL-1β. Internalization of 
gp130 was dependent on p38 and stimulation of monocytes with IL-1β led to an increased 
phosphorylation of serine 782. Furthermore, downstream signaling of IL-6 was affected by 
IL-1β, which again depended on p38.  
To study these regulatory effects in vivo, two transgenic mouse lines were generated. 
Overexpression of gp130-wildtype (wt) or gp130-mutant (mut) was restricted to 
hematopoietic cells. In gp130-mut mice serine residues in the cytoplasmic domain were 
mutated to alanine to create non-phosphorylatable residues, which was assumed to prevent 
internalization and stabilize gp130 surface expression in response to stress stimuli. Two 
preliminary findings might support our expectations: 1) IL-1β had a stronger inhibitory effect 
on gp130 surface expression on cluster of differentiation (CD)11b+ splenocytes from gp130-
wt mice compared to gp130-mut animals. 2) In a model of leukocyte infiltration into the 
peritoneal cavity more cells were recruited in gp130-mut than in gp130-wt mice. Given the 
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known role of IL-6 in migration, this supports the assumption that the altered stability of 
gp130 surface expression influences cell behavior. 
A particular role in chronic inflammation is attributed to IL-6. Raised serum levels of IL-6 and 
sIL-6R have been associated with different chronic inflammatory disorders such as 
inflammatory bowel disease (IBD) or juvenile idiopathic arthritis (JIA). In this study gp130 
surface expression on peripheral monocytes from pediatric IBD patients was shown to be 
increased compared to healthy controls. This was reflected in the level of downstream 
signaling. Specifically, monocytes from IBD patients displayed enhanced STAT3 
phosphorylation. The clinical and pathophysiologic significance of this differential regulation 
remained unclear. However, these findings were reproduced in a murine model of chronic 
colitis, thus presenting a platform for future analyses.  
Reduced gp130 surface expression was found on synovial fluid (SF) monocytes compared to 
peripheral blood (PB) monocytes in JIA patients. By incubating healthy peripheral blood 
mononuclear cells (PBMCs) with SF biochemical abnormalities of SF monocytes were 
partially reproduced. This included gp130 downregulation, which depended on p38. 
In summary, in the framework of this thesis it was shown that gp130 surface expression on 
human monocytes is regulated by the pro-inflammatory cytokine IL-1β, which impairs IL-6-
mediated downstream signaling. This mechanism might be of relevance in inflammatory 
conditions exemplified by inflamed joints of JIA patients. The herein generated transgenic 
mice may be of value for future investigations of the role of crosstalk regulation in chronic 
inflammatory situations. 
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Zusammenfassung 
Das Glycoprotein 130 (gp130) ist das gemeinsame Signalübertragungselement aller 
Interleukin (IL)-6 Typ Zytokine. Gp130-vermittelte Signale spielen eine wichtige Rolle in 
unterschiedlichen biologischen Prozessen wie beispielsweise der Hämatopoese, in 
Zelldifferenzierungen und Immunreaktionen. Um Signale in die Zelle weiterzuleiten, muss 
zunächst ein Komplex aus gp130 und der Liganden-spezifischen α-Rezeptorkette gebildet 
werden. Signalwege, die durch gp130 induziert werden, umfassen die „Janus kinase/signal 
transducer and activator of transcription“ (JAK/STAT) und die „Src homology 2-domain 
containing tyrosine phosphatase/extracellular-regulated kinase“ (SHP2/ERK) Kaskade. 
Während gp130 auf den meisten Zellen gefunden wird, ist die Expression der Liganden-
bindenden Rezeptorketten auf einige Zelltypen beschränkt. Aus diesem Grund wurde lange 
Zeit angenommen, dass das Expressionsmuster der α-Rezeptoren die Sensitivität von Zellen 
für IL-6 Typ Zytokine bestimmt. Die Expression von gp130 kann jedoch abhängig vom 
regulatorischen Status einer Zelle variieren. Die Bedeutung einer streng regulierten gp130 
Oberflächenexpression wird außerdem dadurch verstärkt, dass der lösliche IL-6 α-Rezeptor, 
sIL-6R, den membrangebundenen Rezeptor ersetzen und so Signale in Zellen auslösen 
kann, die nur gp130 exprimieren. 
In Leberzellen wurde eine schnelle Herunterregulation der gp130 Oberflächenexpression 
durch pro-inflammatorische Zytokine beschrieben. Diese Herunterregulation war durch die 
stress-induzierte Kinase p38, die Phosphorylierung von Serin 782 in der zytoplasmatischen 
Domäne von gp130 und eine nachfolgende Internalisierung und den Abbau des Rezeptors 
vermittelt. Die reduzierte Verfügbarkeit des Rezeptors an der Zelloberfläche beeinträchtigte 
die IL-6 induzierte STAT3 Aktivierung. Da IL-6 eine wichtige Rolle in verschiedenen 
Immunreaktionen spielt, sollte in dieser Arbeit ermittelt werden, ob der in Leberzellen 
gezeigte regulatorische Mechanismus in humanen Monozyten von Bedeutung sein könnte. 
Mit Hilfe unterschiedlicher experimenteller Ansätze konnte bestätigt werden, dass gp130 
nach der Stimulation mit pro-inflammatorischem IL-1β internalisiert wurde. Diese 
Internalisierung war abhängig von p38 und die Stimulation von Monozyten mit IL-1β führte zu 
einer verstärkten Phosphorylierung von Serin 782. Weiterhin war die IL-6 induzierte 
Signalübertragung durch IL-1β beeinträchtigt, was wiederum auf der Wirkung von p38 
beruhte. 
Um diese regulatorischen Mechanismen in vivo untersuchen zu können, wurden im Rahmen 
der Arbeit zwei transgene Mauslinien generiert. Die Überexpression von gp130-Wildtyp (Wt) 
oder einer gp130-Mutante (Mut) war unter Kontrolle des VAV-Promoters auf 
hämatopoetische Zellen beschränkt. In gp130-Mut Tieren wurden Serinreste in der 
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zytoplasmatischen Domäne zu Alaninen mutiert, so dass diese nicht mehr phosphoryliert 
werden können. Es wurde angenommen, dass dies die Internalisierung als Reaktion auf 
Stress vermindern und damit die gp130 Oberflächenexpression erhöhen sollte. Zwei erste 
Beobachtungen haben die Erwartungen teilweise bestätigt: 1) IL-1β hatte einen stärkeren 
inhibitorischen Effekt auf die gp130 Oberflächenexpression auf cluster of differentiation 
(CD)11b+ Splenozyten von gp130-Wt Mäusen im Vergleich zu gp130-Mut Tieren. 2) In einem 
Modell zur Untersuchung von Leukozyteninfiltration in die Bauchhöhle wurden mehr Zellen in 
gp130-Mut als in gp130-Wt Mäusen rekrutiert. Aufgrund der bekannten Rolle, die IL-6 bei 
Migrationsprozessen spielt, können diese Ergebnisse die Annahme bestätigen, dass eine 
veränderte Stabilität der gp130 Oberflächenexpression das migratorische und 
inflammatorische Verhalten der Zellen beeinflusst. 
IL-6 wird eine besondere Rolle in chronischen Entzündungssituationen zugeschrieben. 
Erhöhte Serum Level von IL-6 und seines löslichen Rezeptors werden mit verschiedenen 
inflammatorischen Krankheiten assoziiert. Darunter fallen chronisch entzündliche 
Darmerkrankungen (CED) oder die juvenile idiopathische Arthritis (JIA). In dieser Arbeit 
wurde gezeigt, dass im Vergleich zu gesunden Kontrollen die gp130 Oberflächenexpression 
auf peripheren Monozyten von Kindern mit CED erhöht war. Dies spiegelte sich auch in der 
Signaltransduktion wider. Hier wiesen Monozyten von CED Patienten eine verstärkte STAT3 
Phosphorylierung auf. Die klinische und pathophysiologische Bedeutung dieser 
differentiellen Regulation wurde noch nicht aufgeklärt. Allerdings konnten die Ergebnisse der 
CED Patienten in einem Mausmodell mit chronischer Kolitis reproduziert werden, was eine 
Basis für weitere Untersuchungen darstellt. 
Bei JIA Patienten wurde eine verringerte gp130 Oberflächenexpression auf Monozyten aus 
Synovialflüssigkeit (SF) im Vergleich zu Monozyten aus Peripherblut (PB) gefunden. Indem 
mononukleäre Zellen aus PB von gesunden Probanden mit SF stimuliert wurden, konnten 
Teile der biochemischen Veränderungen von SF Monozyten reproduziert werden. Dies 
schloss die Herunterregulation von gp130 ein, welche abhängig von p38 war. 
Zusammenfassend wurde im Rahmen dieser Arbeit gezeigt, dass die gp130 
Oberflächenexpression auf humanen Monozyten durch das pro-inflammatorische Zytokin 
IL-1β reguliert wird, was als Konsequenz die IL-6 abhängige Signaltransduktion 
beeinträchtigt. Wie am Beispiel von entzündeten Gelenken von JIA Patienten dargestellt, 
könnte dies für chronisch inflammatorische Erkrankungen von Bedeutung sein. Die 
generierten transgenen Mäuse können in Zukunft dazu beitragen, die Rolle dieser 
Regulationsmechanismen in entzündlichen Situationen weiter zu untersuchen.
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Abbreviations 
°C   Degree Celsius 
µ-  Micro- 
 
AIA  Antigen-induced arthritis 
APC    Allophycocyanin  
APP  Acute phase protein 
 
BSA    Bovine serum albumin 
 
CD    Cluster of differentiation 
CD  Crohn’s disease 
cDNA  Complementary DNA 
CIA  Collagen-induced arthritis 
CLC  Cardiotrophin-like cytokine 
CNTF  Ciliary neurotrophic factor 
ct    Cycle threshold 
CT-1  Cardiotrophin-1 
 
Da  Dalton 
DC  Dendritic cell 
dd H2O    Double distilled H2O 
DMSO  Dimethylsulfoxide 
DNA   Desoxyribonucleic acid 
DSS    Dextrane sodium sulfate 
DTT    Dithiotreitol 
 
ECL  Enhanced chemiluminescence 
E. coli   Escherichia coli 
EDTA   Ethylene diamine tetraacetic acid 
e.g.  For example 
ERK  Extracellular signal-regulated kinase 
EtOH  Ethanol 
 
FACS   Fluorescence activated cell sorting 
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FCS    Fetal calf serum 
FITC    Fluorescein 
 
g  Gram 
g  Gravitational acceleration (9.81 m/s2) 
GFP    Green fluorescent protein 
gp80  Glycoprotein 80 
gp130  Glycoprotein 130 
 
h  Hour(s) 
HRP    Horseradish peroxidase  
HS  Human serum 
IBD  Inflammatory bowel disease 
IL  Interleukin 
IL-1Ra  Interleukin-1 receptor antagonist 
IL-6R  Interleukin-6 receptor 
i.p.    Intraperitoneal 
IP  Immunoprecipitation 
IgG    Immunglobulin G 
IL    Interleukin  
 
JAK  Janus kinase 
JIA    Juvenile idiopathic arthritis  
 
kDa  Kilo Dalton 
 
l  Liter 
LIF  Leukemia inhibitory factor 
LP  Lamina propria 
LPS  Lipopolysaccharide 
 
m  Milli- 
M  Molar 
MAPK  Mitogen-activated protein kinase 
M-CSF Macrophage colony-stimulating factor 
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M-CSFR Macrophage colony-stimulating factor receptor 
MEF  Murine embryonal fibroblast 
MFI    Meanfluorescence intensity 
min  Minute(s) 
MK2  Mitogen-activated protein kinase-activated kinase 2 
mRNA  Messenger RNA 
NF- κB  Nuclear factor-κB 
NP  Neuropoeitin 
ns  not significant 
 
ON  Overnight 
OSM  Oncostatin M 
 
PB    Pacific blue  
PB  Peripheral blood 
PBMCs   Peripheral blood mononuclear cells 
PBS    Phosphate buffered saline 
PCR  Polymerase chain reaction 
PE    Phycoerythrin 
Pen/Strep    Penicillin/Streptomycin 
PFA    Paraformaldehyde 
PI3K  Phosphatidyl-inositol-3-kinase  
PIAS  Protein inhibitors of activated STAT 
p-STAT Phosphorylated STAT 
PVDF   Polyvinyliden fluorid 
 
R  Receptor 
RA  Rheumatoid arthritis 
RANKL Receptor activator of nuclear factor-κB ligand 
RNA  Ribonucleic acid 
RPL13A Ribosomal protein L13A 
RPMI  Roswell Park Memorial Institute 
RT  Room temperature 
RT-PCR Real time polymerase chain reaction 
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SCID  Severe combined immunodeficiency 
SDS    Sodium dodecylsulfate 
SDS-PAGE  SDS-polyacrylamid gelelectrophoresis  
sec  Second(s) 
SF  Synovial fluid 
SFMCs Synovial fluid mononuclear cells 
sgp130 Soluble gp130 
sIL-6R  Soluble IL-6R 
SH2  Src homology 2 
SHP2  SH2-domain containing protein tyrosine phosphatase 2 
STAT    Signal transducer and activator of transcription 
 
TBE   Tris-buffered saline electrophoresis buffer  
TBS-T  Tris-buffered saline containing 0.05% (v/v) tween-20 
TEMED  N,N,N’,N’-tetramethylen-ethylendiamin  
TG  Transgenic 
TGF    Transforming growth factor 
Th  T helper 
TNFα    Tumor necrosis factor-α 
Treg  Regulatory T cell 
Tyr  Tyrosine 
 
UC  Ulcerative colitis 
 
v/v   Volume per volume  
 
WB  Western blot 
WT   Wild type 
w/v   Weight per volume  
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1 INTRODUCTION 
1.1 The signal transducer gp130 
The glycoprotein 130 (gp130, CD130) is the signal transducing element common to all 
interleukin (IL)-6 type cytokines. It mediates several different, in part redundant, biological 
activities. Gp130 plays an essential role in developmental processes, which is critically 
demonstrated by the lethality observed in gp130 knockout mice. These animals display 
hypoplasia of the ventricular myocardium and severe defects in hematopoiesis, resulting in 
perinatal death (Yoshida et al., 1996). Postnatal deletion of gp130 in hematopoietic stem 
cells, endothelial and liver cells by conditional knockout leads to several disorders affecting 
the heart, brain, liver and lung. Furthermore, abnormalities in hematopoiesis and immune 
response to pathogens have been observed (Betz et al., 1998). 
Apart from IL-6 itself, the IL-6 cytokine family comprises IL-11, IL-27, IL-31, oncostatin M 
(OSM), leukemia inhibitory factor (LIF), cardiotrophin-1 (CT-1), ciliary neurotrophic factor 
(CNTF), cardiotrophin-like cytokine (CLC) and neuropoeitin (NP) (Diveu et al., 2004). To 
exert their effects on target cells the cytokines use different complexes of α- and β-receptors. 
While IL-6 and IL-11 signal via a homodimer of the β-receptor gp130 combined with their 
respective non-signaling α-receptor subunits, all other members use heterodimers of gp130 
and one of the other β-receptors LIF receptor (LIFR), OSM receptor (OSMR) or IL-27 
receptor (IL-27R/WSX-1). An exception is the cytokine IL-31, which binds to a heterodimer of 
OSMR and the gp130-like protein IL-31 receptor A (Garbers et al., 2012). 
Activation of gp130 triggers three different signaling cascades, most prominently the Janus 
kinase/signal transducer and activator of transcription (JAK/STAT) pathway. JAKs are 
constitutively associated with the cytoplasmic tail of gp130 and become activated upon 
ligand-induced complex building (Stahl et al., 1994). This leads to phosphorylation of specific 
receptor tyrosine residues, which serve as docking sites for Src homology 2-domain 
containing tyrosine phosphatase (SHP2) and STAT proteins, respectively. Once recruited, 
STATs are phosphorylated on a single tyrosine, build dimers and translocate to the nucleus, 
where they bind to their target gene promoters. Within the STAT family, comprising seven 
members, signaling through gp130 typically activates STAT3, to a minor extent STAT1 and 
in some cases STAT5 (Heinrich et al., 2003). Both of the other gp130-mediated signaling 
pathways start with recruitment of the adapter protein SHP2 to the receptor. Like STAT 
proteins, SHP2 is phosphorylated after binding to gp130. It interacts with several other 
proteins, resulting in the activation of the extracellular signal-regulated kinase (ERK) 1/2 and 
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phosphatidyl-inositol-3-kinase (PI3K) (Eulenfeld et al., 2012). Figure 1-1 illustrates the 
different cascades initiated by IL-6-mediated gp130 activation.  
 
 
Figure 1-1: Signaling pathways activated by IL-6  
Binding of IL-6 to IL-6Rα triggers the association of a hexameric signaling complex, composed of two 
IL-6Rα subunits and a gp130 homodimer. Constitutively associated JAKs are activated upon complex 
building and phosphorylate specific tyrosine residues within the cytoplasmic domain of gp130, which 
serve as docking sites for SHP2 and STAT. Binding to the receptor results in phosphorylation and 
activation of STAT and SHP2, subsequently leading to the initiation of dimerization and translocation 
to the nucleus and of the PI3K- and mitogen-activated protein kinase (MAPK)-cascade, respectively. 
[From (Eulenfeld et al., 2012)] 
Endocytosis of the complex formed by ligand binding of IL-6 to its receptor has been 
observed in various cell lines, and is dependent on di-leucine motifs within the cytoplasmic 
tail of gp130 (Dittrich et al., 1994). It became clear that no signal is necessary for the 
internalization of gp130, but that instead it is internalized in a constitutive manner (Thiel et 
al., 1998b).  
While the expression of cytokine-specific receptor chains is restricted to particular cell types, 
chiefly hepatocytes, monocytes/macrophages, neutrophils and some lymphocyte subsets, 
gp130 is ubiquitously expressed. Since none of the IL-6-type cytokines can signal through 
gp130 alone, it has long been widely assumed that the expression of cytokine-specific 
receptors determines the responsiveness of target cells. In 1992, a soluble form of the 
IL-6Rα (sIL-6R) was detected in human plasma of healthy individuals (Honda et al., 1992). 
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This soluble receptor binds to IL-6 with similar affinity as the membrane-bound IL-6R and the 
complex formed this way is able to associate with gp130 and to stimulate target cells. Thus, 
binding of IL-6 to sIL-6R renders cells that express gp130 but not IL-6R responsive, a 
process called trans-signaling (Rose-John and Heinrich, 1994) (figure 1-2 B). Soluble IL-6R 
can be derived either by alternative splicing or by enzymatic shedding from cell membranes. 
Although recombinant soluble receptors of other IL-6-type cytokines have been studied 
in vitro, IL-6 is the only cytokine of the family that uses classical and trans-signaling in vivo 
(Garbers et al., 2012). 
 
Figure 1-2: Classical IL-6 signaling vs. trans-signaling and the antagonistic function of sgp130  
A) Classical signaling is initiated by the binding of IL-6 to its membrane-bound IL-6R, which leads to 
the recruitment of two gp130 molecules and to signal transduction. B) Trans-signaling begins with the 
binding of IL-6 to its soluble receptor sIL-6R. The complex formed interacts with gp130 on target cells, 
which again initiates homodimerization of gp130 and signaling. C) Soluble gp130 (sgp130) competes 
with the membrane-bound receptor for IL-6/sIL-6R complexes. Due to absence of an IL-6 binding site 
within gp130, the interaction is possible only with IL-6 bound to its α-receptor. The antagonistic effect 
of sgp130 is restricted to trans-signaling, since its connection with membrane-bound IL-6/IL-6R is 
inhibited by steric hindrance. [Modified from (Mitsuyama et al., 2006)] 
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In contrast to sIL-6R, sgp130, derived by differentially spliced mRNA, has an antagonistic 
effect. Interestingly, sgp130 turned out to inhibit only IL-6 trans-signaling but not classical 
signaling, i.e. responses via membrane-bound IL-6R (Jostock et al., 2001). This is explained 
by the fact that IL-6 does not bind directly to gp130 but that instead the two forms of gp130 
compete for IL-6/sIL-6R complexes (figure 1-2 C). It was therefore proposed that sgp130 
acts as a natural inhibitor of IL-6 trans-signaling. 
1.2 Regulation of IL-6 signaling 
Since dysregulation of gp130-mediated signaling leads to severe autoimmune diseases such 
as inflammatory bowel disease (IBD) or rheumatoid arthritis (RA), a tight control of cytokine 
action is indispensable. Different mechanisms of regulation, especially of the JAK/STAT 
pathway, have been identified, which can be divided into classical regulatory mechanisms 
and control by cytokine crosstalk. All of the mechanisms mentioned in this chapter are 
summarized in figure 1-3. 
1.2.1 Classical regulators 
An important role as inhibitors of gp130-mediated signaling has been attributed to the 
8-member family of suppressors of cytokine signaling (SOCS): cytokine-inducible SH2 
protein (CIS) and SOCS1-7. Acting as classical feedback inhibitors, SOCS proteins are 
synthesized in response to the JAK/STAT cascade and potently inhibit STAT-mediated as 
well as SHP2-mediated signal transduction (Wormald and Hilton, 2004). The mechanisms by 
which SOCS proteins inhibit cytokine signaling vary among family members. While SOCS1 
has been found to bind to proteins of the JAK family, thereby inhibiting their catalytic function, 
SOCS3 interacts directly with gp130 and impedes JAK activity as well. This inhibitory effect 
seems to be based on a combination of kinase inhibition by kinase inhibitory region and 
targeting of the interacting protein to proteasomal degradation (Sasaki et al., 2000; Zhang et 
al., 1999). SOCS3 is the suppressor crucial for the regulation of IL-6-induced STAT3 
activation and shares its interaction site tyrosine 759 (tyrosine 757 in mice) of gp130 with 
SHP2 (figure 1-1). Mice with a mutated tyrosine 757 show abolished SHP2- and SOCS3-
binding resulting in impaired MAPK-signaling and enhanced activation of STAT, which is not 
sensitive to SOCS3 regulation anymore. Phenotypically the shift in equated STAT- and 
MAPK-signaling is manifested by gastric adenomas and splenomegaly (Tebbutt et al., 2002). 
Thus, tyrosine 757/9 determines the balance between STAT- and MAPK-pathways with 
important (patho-) physiological impact.  
Apart from its function as an adaptor protein contributing to the activation of the MAPK- and 
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PI3K-cascades, an inhibitory function on IL-6 signaling has been described for SHP2. It has 
been shown that overexpression of dominant negative SHP2 mutants leads to enhanced 
phosphorylation of gp130, JAK, STAT and SHP2 (Lehmann et al., 2003). As a tyrosine 
phosphatase, SHP2 may dephosphorylate different elements of the gp130-JAK signaling 
axis. Other protein tyrosine phosphatases (PTPs) have been reported to be involved in the 
regulation of JAK/STAT signaling (Tanuma et al., 2001), but the physiological relevance and 
impact of PTPs on IL-6-induced signaling in vivo remains to be elucidated.   
Protein inhibitors of activated STAT (PIAS) are constitutively expressed and interfere with 
STAT-mediated gene transcription by different molecular mechanisms. The first member 
PIAS1 was found to specifically inhibit STAT1, while the later identified PIAS3 exclusively 
interacts with STAT3 (Chung et al., 1997) (figure 1-3). Both of them bind to the dimeric but 
not the monomeric form of STATs and block their DNA binding activity.  
1.2.2 Crosstalk regulation 
In physiological conditions, where the impact of many different cytokines needs to be 
orchestrated in a way that generates an appropriate biological response, cytokine crosstalk is 
of particular importance. 
The two major pro-inflammatory cytokines IL-1β and tumor necrosis factor (TNF)-α are 
secreted by blood monocytes and macrophages upon activation and are found at most sites 
of inflammation. They induce the release of several other cytokines and chemokines like IL-6 
and IL-8 from tissue cells, monocytes or macrophages. Different crosstalk mechanisms 
between IL-6 and the pro-inflammatory mediators IL-1β and TNF-α have been described, 
including synergistic as well as antagonistic interactions. 
Due to its crucial role in the acute phase response, crosstalk regulation of IL-6 signaling has 
been studied extensively in hepatocytes. The first hints of an inhibitory effect of IL-1β on 
IL-6-dependent acute phase protein (APP) production were discovered in the late 1980s 
(Andus et al., 1988). While these suppressive actions concern class II APPs, an enhanced 
expression of class I APPs has been described in response to IL-1β and IL-6. 
Mechanistically, both effects seem to involve nuclear factor (NF)-κB induced by IL-1β. A 
physical interaction between phosphorylated (p-)STAT3 and NF-κB can either function as 
transcriptional enhancer or repressor depending on the gene (Bode et al., 2012; Yoshida et 
al., 2004) (see figure 1-3).  
In addition to these effects on late phase STAT3 activation an immediate inhibition on 
IL-6-induced STAT3 phosphorylation not only by IL-1β but also by other pro-inflammatory 
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stimuli, such as TNF-α and LPS, has been reported by different groups. 
In primary and cell culture macrophages TNF-α and LPS have been shown to induce SOCS3 
expression and thereby inhibit IL-6-triggered STAT3 phosphorylation. The stress-dependent 
MAPK p38 was hypothesized to be involved especially in the suppression mediated by 
TNF-α (Bode et al., 1999). Ehlting et al. have reported that TNF-α enhances SOCS3 
expression by mRNA stabilization (Ehlting et al., 2007). This stabilization and the basal 
SOCS3 expression are impaired in fibroblasts and macrophages deficient for the p38 
downstream target MAPK-activated kinase 2 (MK2). An IL-1β-dependent stabilization of 
SOCS3 mRNA has been shown as well (Yang et al., 2004) (figure 1-3). 
 
Figure 1-3: Regulation of IL-6 signaling  
After initiation of the JAK/STAT cascade, p-STAT3 induces the feedback inhibitor SOCS3, which 
interferes with JAK activity. Other classical inhibitors are represented by the constitutively expressed 
PIAS and the protein phosphatase SHP2. Binding of IL-1β to its receptor complex leads to the 
activation of NF-κB, which can associate with p-STAT3 and enhance or repress the activation of class 
I and class II APPs, respectively. The MAPK p38, activated in response to IL-1β, phosphorylates MK2 
and thereby affects IL-6 signaling by two mechanisms: 1) it stabilizes SOCS3 mRNA by inhibiting its 
degradation and 2) it phosphorylates serine 782 in gp130, followed by internalization and degradation 
of the receptor. [Adapted from (Garbers et al., 2012)] 
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P38 turned out to be a key molecule in the crosstalk inhibition of IL-6 signaling, accounting 
for further observed effects, such as TNF-α-induced SHP2 recruitment to gp130 (Bode et al., 
2003). Another influence of p38 on IL-6 signaling in response to pro-inflammatory cytokines 
and stress stimuli was shown by Radtke et al. in hepatocytes. Here, p38-dependent 
activation of MK2 leads to phosphorylation of gp130 on serine 782, located upstream of the 
di-leucine internalization motif, followed by increased internalization and degradation of the 
receptor (figure 1-3). The authors conclude that serine 782 is a stress sensor responsible for 
limitation of gp130 signaling. The loss of cell surface-bound gp130 results in impaired IL-6-
induced STAT3 phosphorylation (Radtke et al., 2010). In line with these observations it has 
previously been suggested that the rapid inhibition of IL-6 signaling by pro-inflammatory 
cytokines in macrophages depends on a target within the cytoplasmic region of gp130 
(Ahmed and Ivashkiv, 2000). These authors and others have also described the crosstalk 
inhibition as being independent of de novo protein synthesis, and thus of SOCS3, but instead 
dependent on p38. A decrease of gp130 levels in primary mouse macrophages in response 
to LPS and TNF-α has been suggested as well (Kiu et al., 2007).  
1.3 Functions of IL-6 signaling 
The most prominent member using gp130 as the signaling subunit of its receptor complex is 
IL-6. IL-6 is a pleiotropic cytokine, which can be secreted by different lymphoid and non-
lymphoid cells and is involved in a wide range of biologic activities on various target cells. 
These include hematopoietic functions, immune regulation, inflammation, antibody 
production and oncogenesis (Naka et al., 2002). Some aspects of the involvement of IL-6 in 
inflammation, cell differentiation and bone metabolism will be discussed in this chapter. 
1.3.1 Inflammation 
IL-6 is a cytokine with pro- and anti-inflammatory properties. Its protective role in a septic 
shock model or in liver injury is countered by its detrimental activity in chronic disease, which 
has been demonstrated by the resistance of IL-6 deficient mice to a number of experimental 
chronic inflammatory conditions (Barton and Jackson, 1993; Klein et al., 2005; Ohshima et 
al., 1998). Moreover, the therapeutic application of an anti-IL-6R antibody has proven 
beneficial in various inflammatory disorders (Choy, 2012; Ito et al., 2004). 
Inflammatory reactions occur in response to infection or tissue injury and are part of the 
normal healing process. IL-6 is one of the first cytokines to be produced in the early stages of 
inflammation and it is the main inducer of the acute phase response, stimulating hepatocytes 
to produce a set of plasma proteins, the APPs. These proteins are important components of 
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the innate immune response and some of them are used frequently as diagnostic markers 
(Gabay and Kushner, 1999). The successful resolution of an inflammatory condition leads to 
restoration of normal tissue architecture and is dependent on the transition from innate to 
adaptive immunity. This progression is characterized by a precise regulation of leukocyte 
recruitment and clearance. IL-6 plays an important role in both of these processes. IL-6 
trans-signaling in particular seems to contribute to the recruitment of leukocytes by inducing 
chemokine secretion from resident tissue cells (Hurst et al., 2001). In addition to these 
indirect effects on leukocyte migration, IL-6 has been shown to directly mediate migration of 
human T cells and monocytes (Clahsen and Schaper, 2008; Weissenbach et al., 2004). The 
clearance of neutrophils, which predominantly account for the initial infiltrate in acute 
inflammation, is critical for the resolution of inflammation. IL-6 may be involved in this 
process by provoking apoptosis of neutrophils (Afford et al., 1992). Conversely, IL-6-
mediated STAT3 activation induces the expression of anti-apoptotic regulators in vitro and in 
some murine models of chronic disease (Atreya et al., 2000; Teague et al., 1997). Whereas 
in the former case IL-6 is beneficial for the transition from innate to adaptive immunity, the 
inability of T cells to enter apoptosis results in their retention within the affected tissue and in 
further promotion of inflammation. Other examples of anti-inflammatory actions of IL-6 are 
the induction of IL-1 and TNF antagonists. In patients receiving recombinant IL-6, plasma 
levels of IL-1 receptor antagonist (IL-1Ra) and the soluble TNF receptor p55 have been 
found to be increased. Moreover, monocyte-derived macrophages produce IL-1Ra upon 
stimulation with IL-6 (Tilg et al., 1994). 
How IL-6 balances these pro- and anti-inflammatory effects remains to be clarified. It has 
been proposed that in acute inflammation the anti-inflammatory properties of IL-6 are 
dominant, whereas in chronic conditions its effects are more deleterious to the organism 
(Jones, 2005). An important factor influencing this balance seems to be sIL-6R. While 
classical signaling seems to occur predominantly on the periphery, trans-signaling is 
upregulated during chronic disease and found mostly at the site of inflammation (Scheller et 
al., 2011).  
1.3.2 Cell differentiation 
IL-6 is relevant for cell differentiation processes such as B cell differentiation or the lineage 
commitment of T cells. In particular the question of whether a naϊve CD4+ T cell differentiates 
into a T helper (Th)17 or a regulatory T cell (Treg) depends essentially on IL-6. Th17 cells 
are often associated with autoimmunity and tissue injury. However, Tregs suppress the 
proliferation of activated T cells and help to maintain self-tolerance. The cytokine 
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transforming growth factor (TGF)-β is needed for the development of both of the T cell 
subsets but the additional presence of IL-6 shifts the differentiation towards Th17 cells 
(Bettelli et al., 2006). 
Another cell differentiation process influenced by IL-6 is the decision whether monocytes give 
rise to dendritic cells (DCs) or to macrophages. Upon having crossed the endothelial barrier, 
monocytes are activated and differentiate depending on local cytokines. In vitro studies have 
shown that after contact with monocytes, fibroblasts secret IL-6, which in turn up-regulates 
the expression of macrophage colony-stimulating factor (M-CSF) receptors on monocytes. 
This enables them to consume their autocrine M-CSF and to skew differentiation towards a 
macrophage phenotype (Chomarat et al., 2000). 
1.3.3 Bone metabolism 
Bone homeostasis is characterized by a strictly regulated balance of bone-forming 
osteoblasts and bone-resorbing osteoclasts (Kwan Tat et al., 2004). IL-6 has been shown to 
promote osteoclastogenesis by different mechanisms. In addition to a direct effect on 
osteoclast precursors (Kudo et al., 2003), IL-6 and other pro-inflammatory cytokines mediate 
the upregulation of receptor activator of nuclear factor-κB ligand (RANKL) (O'Brien et al., 
1999). In association with M-CSF RANKL induces osteoclast formation from CD14+ 
precursors (Nicholson et al., 2000; Quinn et al., 1998). 
1.4 Gp130 in inflammation and autoimmunity 
Regulation of inflammation is mainly controlled by cytokines and an imbalance between pro- 
and anti-inflammatory cytokines may lead to autoimmunity and chronic inflammation. Under 
these conditions the natural course of the inflammatory response is lost, which can lead to 
tissue damage and disease progression rather than resolution. The growing number of 
cytokine-targeting therapies reflects their importance during the development and 
perpetuation of chronic inflammatory diseases.  
Among the cytokines signaling via gp130, IL-6 plays a unique role in inflammation and 
autoimmunity. The resistance of IL-6 knockout mice to several inflammatory conditions has 
not been found for other IL-6-type cytokines. IL-27, for instance, has been reported to 
suppress collagen-induced arthritis (CIA) and mice deficient in IL-11Rα and OSM-Rβ have 
shown a susceptibility towards antigen-induced arthritis (AIA) similar to that found in wildtype 
mice (Niedbala et al., 2008; Wong et al., 2006b). Furthermore, recombinant IL-11 has a 
protective effect in animal models of colitis, as well as in patients with IBD (Mitsuyama et al., 
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2006). Increased levels of IL-6 and sIL-6R in patients suffering from chronic inflammatory 
disorders have been reported in several studies, further underlining the crucial role played by 
gp130-mediated IL-6 signaling (Jones et al., 2001).  
1.4.1 Inflammatory bowel disease 
Crohn’s disease (CD) and ulcerative colitis (UC) are the two major types of inflammatory 
bowel diseases and are characterized by chronic recurrent inflammation of the 
gastrointestinal tract. IBD pathogenesis is complex, involving genetic factors, innate and 
adaptive immune responses, the intestinal microbial flora and epithelial barrier function 
(Murphy et al., 2012). A range of locally produced cytokines leads to inflammation and 
damage of intestinal epithelial cells (IECs).  
IL-6 has been found to be elevated in serum and colonic tissue of IBD patients and its levels 
correlate with disease activity (Mitsuyama et al., 1991). Studies using dextrane sodium 
sulfate (DSS)-induced colitis in mice have reported an increased production of IL-6, while 
IL-6 deficient mice show limited pathological signs of experimental colitis, thus confirming the 
crucial role of the cytokine (Suzuki et al., 2001).  
Consistent with enhanced IL-6 levels, the downstream signal molecule STAT3 has been 
highlighted as a major player in IBD with different biological functions. While many studies 
have explored the role of p-STAT3, less interest has been focused on SHP2-mediated 
signals. Increased STAT3 activation has been described for cells of the lamina propria (LP) 
and IECs in human IBD and in different murine colitis models, where a correlation with 
disease severity has been reported (Mudter et al., 2005; Suzuki et al., 2001). However, other 
investigators have reported evidence of a protective effect of STAT3 phosphorylation in IECs 
of DSS-treated mice and development of spontaneous chronic enterocolitis with age in 
macrophage- and neutrophil-specific STAT3 knockout mice (Grivennikov et al., 2009; 
Takeda et al., 1999). This phenotype closely resembles that of IL-10 deficient mice, reflecting 
the anti-inflammatory effects of p-STAT3 in response to cytokines of the IL-10 family. One 
member of this family, IL-22, has been shown to be an important inducer of STAT3 
phosphorylation in IECs during colitis, being responsible for the expression of anti-apoptotic 
and pro-proliferative genes, which contribute to resolution of inflammation and wound healing 
(Neufert et al., 2010). In contrast, STAT3 activity in T cells of the lamina propria perpetuates 
chronic inflammation. A study using a murine experimental colitis model mediated by Th1 
cells has reported an enhanced resistance of mucosal T cells to apoptosis, which was 
ascribed to IL-6-mediated STAT3 activation. Interestingly, most of these T cells do not 
express IL-6R on their surface, pointing to IL-6 trans-signaling as the pivotal pathway. 
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Indeed, treatment with a gp130-Fc fusion protein that mimics sgp130 and thereby specifically 
inhibits IL-6 trans-signaling has been shown to suppress colitis activity in mice (Atreya et al., 
2000). Since a large amount of IL-6 in the circulation of IBD-patients is found in a complex 
with sIL-6R, treatment with gp130-Fc might represent a promising therapeutic approach. First 
clinical trials are planned for 2013 (Rose-John, 2012). In contrast to tocilizumab, an antibody 
against IL-6R, which is commonly used as a treatment of IBD, gp130-Fc can be expected to 
produce fewer side-effects and a more specific efficacy, because not all IL-6 functions are 
blocked. 
The ambiguous role of STAT3 in IBD is further supported by studies in mice deficient in IL-6 
and those with disrupted gp130-mediated STAT-signaling. Both of them show impaired 
gastrointestinal wound healing, possibly due to reduced survival and proliferation of IECs 
(Ernst et al., 2001; Kopf et al., 1994). On the other hand, a conditional gp130 knockout 
protects against DSS-induced colitis and gp130 deficiency in neutrophils and macrophages 
delays and reduces disease activity (Sander et al., 2008). Thus, concerning the role of 
STAT3, it is important to distinguish between different cell populations and origins of 
signaling. I.e. mice unable to produce gp130-mediated STAT3 signaling in neutrophils and 
macrophages are still capable of activating STAT3 in response to IL-10, while those with an 
STAT3 deficiency in the same cell types cannot do so. Whereas in the former the missing 
STAT3 signal has a protective effect regarding colitis induction, in the latter the lack of anti-
inflammatory IL-10 signaling seems to overcome the protective effects. 
In line with increased levels of IL-6 and activated STAT3 in IBD, the negative feedback 
inhibitor SOCS3 is augmented. However, its expression may not be sufficient to shut off 
STAT3 activity (Li et al., 2012). This could be due to the extremely high IL-6 levels or to 
posttranslational modifications of SOCS3, impairing its function. Mice expressing a dominant 
negative SOCS3 mutant were more susceptible to DSS-induced colitis than their wildtype 
littermates suggesting its involvement in pathogenesis (Suzuki et al., 2001). 
A loss of SOCS3 in IECs has been described in colorectal cancer, the risk of which is 
increased in IBD. This may further promote the anti-apoptotic and pro-proliferative role 
attributed to p-STAT3 in such conditions. 
Other cytokines raised during initial inflammation and shown to be key players in IBD are the 
pro-inflammatory cytokines IL-1β and TNF-α, the expression of which is increased in IBD 
patients and in different mouse models of colitis. The pivotal role of TNF-α in the 
pathogenesis of IBD is reflected in the clinical use of different anti-TNF agents. Interestingly, 
the efficacy of these substances differs among patients (Horiuchi et al., 2010).   
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1.4.2 Juvenile idiopathic and rheumatoid arthritis  
Rheumatoid and juvenile idiopathic arthritis (JIA) refer to a group of chronic arthritic disorders 
in adult- and childhood, respectively. JIA is the most common pediatric rheumatic condition, 
defined by an onset before the age of 16 years and persistence for at least 6 weeks. Of 7 
differentiated subtypes, the highest frequency is found for oligoarthritis, followed by 
polyarthritis and systemic-onset arthritis (Ravelli and Martini, 2007). Both of the conditions, 
RA and JIA, are characterized by chronic recurrent inflammation targeting mainly the 
synovial membrane, cartilage and bone resulting in joint effusion, swelling, pain, restriction of 
physical activity and systemic complications. The pathogenesis is multifactorial, involving 
genetic and environmental factors, a breakdown of self-tolerance, innate and adaptive 
immune responses. Different cytokines and chemokines can be detected at high levels within 
serum and synovial fluid (SF) and an imbalance between pro- and anti-inflammatory factors 
is a key feature of the disease (Kutukculer et al., 1998; McInnes and Schett, 2007).  
RA and JIA go along with increased levels of IL-6 and sIL-6R. An association between IL-6 
levels in the SF and markers of inflammation has been reported for RA, while for systemic 
JIA levels of circulating IL-6 correlate with disease activity (Gabay and Kushner, 1999). IL-6 
deficient mice are largely resistant to the induction of experimental arthritis. This is 
accompanied by reduced synovial infiltration, lower IL-17 levels and fewer osteoclasts, which 
promote bone destruction. The administration of IL-6 to IL-6-/- mice is not sufficient to restore 
disease. However, the sIL-6R-IL-6 fusion protein (HYPER-IL-6) reconstitutes AIA and 
sgp130 alleviates disease in wildtype animals, emphasizing the importance of IL-6 trans-
signaling in arthritis (Nowell et al., 2003). Thus, the decreased synovial infiltration seen in 
sgp130-treated wildtype mice compared to non-treated mice after induction of arthritis is 
consistent with the idea that IL-6 trans-signaling plays a major role in the recruitment of 
mononuclear cells to areas of inflammation. Furthermore, the role of IL-6 in bone metabolism 
is represented by reduced numbers of osteoclasts in IL-6 deficient mice after the induction of 
AIA. Destruction of articular cartilage and bone is a hallmark in JIA and RA (Gravallese et al., 
1998). 
The anti-apoptotic and pro-proliferative properties of p-STAT3 have been highlighted to 
contribute essentially to pathogenesis of RA. Hyperplasia of the synovial membrane is a 
characteristic feature of arthritis and synovial fibroblasts show a number of abnormalities in 
RA patients, such as resistance to the induction of apoptosis and elevated proliferation. 
Overexpression of dominant negative Stat3 in RA synovial fibroblasts leads to increased 
apoptosis and reduced proliferation (Krause et al., 2002). In addition to these functions of 
p-STAT3 in synovial fibroblasts, similar effects have been observed in T cells at sites of 
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inflammation. IL-6 thereby contributes to synovial infiltration not only by recruiting 
mononuclear cells but also by promoting their maintenance at the site of inflammation. In 
accordance with the pro-inflammatory role of p-STAT3, mice with a mutation of the shared 
binding site for SHP2 and SOCS3 within the cytoplasmic domain of gp130 spontaneously 
develop inflammatory joint disease similar to RA. These mice display enhanced STAT and 
especially STAT3 activation due to the missing counterregulation by SOCS3 and SHP2 
(Atsumi et al., 2002). On the other hand, RA-like joint pathology has been reported for mice 
with disrupted STAT-binding sites of gp130 as well. Overactivation of SHP2/ERK, caused by 
the missing feedback inhibition by SOCS proteins, leads to increased proliferation of synovial 
fibroblasts and chondrocytes (Ernst et al., 2001). Mice lacking SOCS3 in the hematopoietic 
and endothelial cell compartment show more severe joint inflammation after the induction of 
experimental arthritis compared to wildtype animals, indicating an important role in the 
regulation of gp130-mediated signaling (Wong et al., 2006a). This is further supported by the 
observation of enhanced SOCS3 expression in synovial tissues of mice during experimental 
arthritis and RA patients. As in the case of IBD, the levels of SOCS3 might still not be 
sufficient to counteract STAT3 activation or it could be that the feedback inhibitor is modified 
or rapidly degraded (Shouda et al., 2001).  
Much attention has been paid to the balance between pro-inflammatory Th17 cells and anti-
inflammatory Tregs in RA and JIA. Several studies indicate high numbers of Tregs within 
inflamed joints despite persisting inflammation, which has raised the question of whether the 
suppressive capacity of these Tregs or the responsiveness of effector T cells is impaired. 
Suppression assays with Tregs isolated from arthritic joints have shown even higher activity 
than their counterparts derived from peripheral blood (van Amelsfort et al., 2004). However, 
effector T cells from SF of RA and JIA patients show resistance to inhibition by functional 
Tregs (Haufe et al., 2011; van Amelsfort et al., 2004). 
As in other chronic inflammatory conditions, high levels of the typical pro-inflammatory 
cytokines TNF-α and IL-1β can be found in arthritic patients and serve as therapeutic targets. 
The use of anti-TNF and -IL-6 agents has been shown to influence the Th17/Treg cell 
balance in the SF of RA patients. Interestingly, Tregs isolated from RA patients treated with 
the anti-TNF antibody adalimumab, but not etanercept, are able to regulate monocyte-
derived IL-6 and thereby suppress Th17 cells (McGovern et al., 2012). The JAK inhibitor 
tofacitinib, which is reported to be effective in clinical studies with RA patients, seems to 
affect T cell responses by suppressing IL-17 and interferon γ production (Tanaka et al., 
2012).  
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1.5 Aim of this study 
IL-6 plays a crucial role in different immune reactions. Together with other IL-6-type 
cytokines, it shares the signal transducer gp130 as part of its receptor. Dysregulated IL-6 
signaling leads to severe inflammatory disorders. One way to restrict cytokine signaling is by 
limiting the availability of their respective receptors on the cell surface. In contrast to the 
ligand-binding α-chain of the IL-6 receptor complex, which is present on few cell types, 
gp130 is ubiquitously expressed. Thus, a strictly regulated surface expression is 
indispensable.  
Previous work has shown that gp130 surface expression on hepatocytes is negatively 
regulated by pro-inflammatory stimuli, which affect downstream signaling.  
The first important aim of this study was therefore to elucidate potential crosstalk regulation 
of IL-6 signaling in immune cells. Since human monocytes express high levels of gp130, 
regulatory mechanisms of the pro-inflammatory cytokine IL-1β were studied in this cell type.  
The objective in the second part of the thesis was to generate transgenic mice that would 
enable crosstalk regulation of gp130-mediated signaling to be explored in vivo. The vav 
promoter was used to drive overexpression stably throughout the hematopoietic 
compartment. One mouse line was generated, which overexpresses a serine-mutated gp130 
that was assumed to impair crosstalk-mediated internalization of gp130. These mice were 
compared to a second mouse strain overexpressing the gp130 wildtype protein. 
IL-6 signaling is of utmost importance in chronic inflammatory disorders. This is exemplified 
by the successful clinical use of an anti-IL-6R antibody and by the resistance of IL-6 deficient 
mice to disease in several inflammatory models. However, the role of IL-6 in inflammation is 
sometimes contradictory and is not completely understood. Thus, the aim in the third part of 
the study was to investigate the expression levels of the IL-6 signaling molecule gp130 in 
chronic inflammatory conditions like IBD and JIA. The identification of regulatory 
mechanisms that control gp130 surface expression and downstream signaling in chronic 
inflammation could contribute to a better understanding and treatment of these diseases. 
All essential steps are illustrated by the flow chart in figure 1-4. 
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Figure 1-4: Flow chart showing the different parts of this PhD thesis. 
Part 1: 
Investigation of crosstalk 
mechanisms in human 
monocytes 
Analysis of gp130 surface 
expression after 
stimulation with IL-1β 
Investigation of IL-6-
induced STAT3 
phosphorylation after 
stimulation with IL-1β 
Mechanistic analyses 
Dependance on p38? 
Phosphorylation of serine-782 
in the cytoplasmic tail of 
gp130? 
Part 2:  
Generation of transgenic 
mice 
Cloning of two contructs: 
(HS21/45) vav-gp130-wt 
and (HS21/45) vav-gp130-
mut 
Generation of transgenic 
mice 
Characterization of 
transgenic mice 
Comparison of gp130 cell 
surface expression and STAT3 
phosphorylation  
Comparison of gp130 cell 
surface expression and STAT3 
phosphorylation after 
stimulation with IL-1β 
Part 3:  
Analysis of gp130 cell 
surface expression in 
chronic inflammatory 
conditions 
Investigation of gp130 
surface expression on 
monocytes from IBD and 
JIA patients 
Analysis of STAT3 
phosphorylation in 
monocytes from IBD and 
JIA patients 
Mechanistic analyses  
Crosstalk regulation in chronic 
disease? 
  MATERIALS AND METHODS 
16 
 
2 MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Consumables and chemicals 
Consumables were purchased from: 
BD Biosciences (Heidelberg), BD Microlance (Ireland), Eppendorf (Hamburg), Greiner Bio-
One (Solingen), Miltenyi Biotec GmbH (Bergisch Gladbach), Peqlab (Erlangen), 
Schleicher&Schuell (Dassel), Starlab GmbH (Ahrensburg), Terumo Europe N.V. (Belgium). 
Laboratory chemicals were purchased from: 
Applichem (Darmstadt), Bio-Rad (Munich), eBioscience (Frankfurt), GE Healthcare (Munich), 
Invitrogen (Karlsruhe), Merck (Darmstadt), Macherey-Nagel (Düren), Millipore (Eschborn), 
MP Biomedicals (USA), Qiagen (Hilden), Roth (Karlsruhe), Sigma Aldrich (Steinheim), 
Thermo Fisher Scientific (Schwerte), Zymo Research (USA). 
2.1.2 Equipment 
Table 2-1: Used equipment 
Equipment Manufacturer 
7300 Real Time PCR System Applied Biosciences (Darmstadt) 
Analytical Balance Sartorius AG (Göttingen) 
Bio Photometer Eppendorf(Wesseling) 
FACS CANTOII  BD Biosciences (Heidelberg) 
Hera Cell Incubator   Thermo Fischer Scientific (Schwerte) 
Heraeus Multifuge 3SR+ Thermo Fischer Scientific (Schwerte) 
Heraeus Pico 17 Centrifuge Thermo Fischer Scientific (Schwerte) 
Microcentrifuge Thermo Fischer Scientific (Schwerte) 
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Lapdancer Digital VWR International GmbH (Darmstadt) 
LAS 3000, Image Reader Fujifilm (Düsseldorf) 
Nano Drop ND 1000 Spectrophotometer PEQLAB Biotechnologie GmbH (Erlangen) 
Opera High Content Screening System PerkinElmer (USA) 
Pipetboy Acu IBS Integra Biosciences (Fernwald) 
Laminar Flow Hood Thermo Fisher Scientific (Schwerte) 
Mini-PROTEAN® 3 Electrophoresis System  BIO-RAD (Munich) 
Semi-Dry Transfer Cell BIO-RAD (Munich) 
Thermomixer Compact Eppendorf (Hamburg) 
Transfer Pipettes S Brand (Wertheim) 
Ultrasonic Sonicator Hielscher (Teltow) 
Ultraviolet Sterilizing PCR Workstation PEQLAB Biotechnologie GmbH (Erlangen) 
 
2.1.3 Reaction kits 
Table 2-2: Used reaction kits 
Kit Manufacturer 
First Strand cDNA Synthesis Kit   Fermentas (St. Leon-Roth) 
NucleoBond® PC500 Macherey-Nagel (Düren) 
qPCR Master Mix for SYBR Green I   Eurogentec GmbH (Cologne) 
RNAse free DNAse Set Qiagen (Hilden) 
RNeasy® Mini Kit Qiagen (Hilden) 
TopTaq DNA Polymerase Qiagen (Hilden) 
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Wizard® SV Gel and PCR Clean-Up System   Promega (Mannheim) 
Zippy Plasmid Miniprep Kit Zymo Research (USA) 
 
2.1.4 Oligonucleotides and plasmids 
Table 2-3: Used oligonucleotides 
Gen Sequence 5’  3’ 
Human RPL13A for: AGGTATGCTGCCCCACAAAAC 
rev: TGTAGGCTTCAGACGCACGAC 
Human SOCS3 for: CACCTGGACTCCTATGAGAAAGTCA 
rev: GGGGCATCGTACTGGTCCAGGAA 
Murine β-actin for: ACTATTGGCAACGAGCGGTTC 
rev: TTACGGATGTCAACGTCACACTTC 
Murine gp130 for RT-PCR for: ATAGTCGTGCCTGTGTGCTTAGC 
rev: GGTGACCACTGGGCAATATGA 
Murine gp130 for genotyping for: CGGCTCATATGGAAGGCACTGCC 
rev: CGCGGCCATTCGGACCATGT 
All primers were ordered from VBC Biotech (Switzerland). 
Table 2-4: Used plasmids 
Plasmid Description 
vav hematopoietic vector pIC-19H vav-hCD4 
SW213 pcDNA3.1 mugp130 wt 
SW214 pcDNA3.1 mugp130 SS/AA 
Vav-gp130wt pIC-19H vav mugp130 wt 
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Vav-gp130mut pIC-19H vav mugp130 SS/AA 
 
2.1.5 Antibodies 
Table 2-5: Used antibodies 
Antibody Clone Manufacturer Application 
Mouse α-human CD14, APC/FITC-
conjugated 
MEM-18 Immunotools 
(Friesoythe) 
FC, FM 
Mouse α-human IL-6R, PerCP-
eFluor® 710-conjugated 
47.7G7.1F2 eBioscience (Frankfurt) FC 
Mouse α-human IL-6R, APC-
conjugated 
17506 R&D Systems FC 
Mouse α-human gp130, FITC-
conjugated 
B-R3 Abcam (UK) FC, FM 
Mouse α-human gp130, PE-
conjugated 
AM64 BD Biosciences 
(Heidelberg) 
FC 
Mouse α-human/mouse STAT3 
(pY705), Alexa Fluor® 647-
conjugated 
4/P-STAT3 
 
BD Biosciences 
(Heidelberg) 
FC 
Mouse α-human/mouse p38 MAPK 
(pT180/pY182), Alexa Fluor® 488-
conjugated 
36/p38 
(pT180/pY182) 
BD Biosciences 
(Heidelberg) 
FC 
Armenian Hamster α-mouse CD3, 
PE/APC-conjugated 
145-2C11 eBioscience (Frankfurt) FC 
Rat α-mouse CD11b, eFluor® 450-
conjugated 
M1/70 eBioscience (Frankfurt) FC 
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Rat α-mouse CD19, FITC-
conjugated 
eBio1D3 eBioscience (Frankfurt) FC 
Rat α-mouse F4/80, APC-
conjugated 
BM8 eBioscience 
(Frankfurt) 
FC 
Rat α-mouse gp130, APC-
conjugated 
KGP130 eBioscience (Frankfurt) FC 
Mouse α-human gp130-pSer782  BD Biosciences 
(Heidelberg) 
WB 
Rabbit α-human/mouse gp130 M-20 Santa Cruz 
Biotechnology (USA) 
IP, WB 
Rabbit α-human/mouse phospho-
STAT3 (Tyr705) 
 Cell Signaling 
Technology (USA) 
WB 
Mouse α-human/mouse STAT3  84/Stat3 BD Biosciences 
(Heidelberg) 
WB 
Goat α-rabbit immunoglobulins, 
HRP-conjugated 
Polyclonal DakoCytomation 
(Denmark) 
WB 
 
2.1.6 Cytokines 
Table 2-6: Used cytokines 
Cytokine Concentration Manufacturer 
Human IL-1β 20 ng/ml PeproTech (Hamburg) 
Human IL-6 20 ng/ml MiltenyiBiotec GmbH (Bergisch Gladbach) 
Human IL-10 20 ng/ml PeproTech (Hamburg) 
Murine IL-1β 20 ng/ml PeproTech (Hamburg) 
Murine IL-6 20 ng/ml MiltenyiBiotec GmbH (Bergisch Gladbach) 
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2.1.7 Inhibitors 
Table 2-7: Used inhibitors 
Inhibitor Concentration Manufacturer 
SB202190 1-5 µM Calbiochem (Darmstadt) 
Actinomycin D 5 µg/ml Sigma Aldrich (Steinheim) 
 
2.1.8 Buffers and media 
Table 2-8: Used buffers and formulation 
Buffer Formulation 
Blocking Buffer 
TBS-T 
10% (w/v) BSA 
Blot Buffer 
25 mM Tris Base  
192 mM Glycine 
0.1% (w/v) SDS 
20% (v/v) Methanol 
FACS Buffer 
PBS 
0.5% (w/v) BSA 
RIPA Buffer 
10 mM Tris-HCL, pH 7,4 
150 mM NaCl 
1% (v/v) NP40 
1% (w/v) Sodium desoxycholate 
0.1% (w/v) SDS 
SDS Running Buffer 
25 mM Tris base 
192 mM Glycine 
2% (w/v) SDS 
SDS Sample Buffer (2x) 
100 mM Tris-HCl, pH 6,8 
4% (w/v) SDS 
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0.2% (w/v) Bromophenol blue 
20% (v/v) Glycerol 
200 mM β-Mercaptoethanol 
Separating Gel, 7.5%  
50% (v/v) Distilled water 
25% (v/v) Separating Gel Tris Solution (4x) 
25% (v/v) Acrylamide 4K Solution (30%), Mix 
37.5:1 
0.1% (w/v) APS 
0.1% (v/v) TEMED 
Separating Gel, 12%  
35% (v/v) Distilled Water 
25% (v/v) Separating Gel Tris Solution (4x) 
40% (v/v) Acrylamide 4K Solution (30%), Mix 
37.5:1 
0.1% (w/v) APS 
0.1% (v/v) TEMED 
Separating Gel Tris Solution (4x) 
1.5 M Tris-HCL, pH 8,8 
0.4% (w/v) SDS 
Stacking Gel  
65% (v/v) Distilled Water 
25% (v/v) Stacking Gel Tris solution (4x) 
10% (v/v) Acrylamide 4K Solution (30%), Mix 
37.5:1 
0.1% (w/v) APS 
0.1% (v/v) TEMED 
Stacking Gel Tris Solution (4x) 
0.5 M Tris-HCL 
0.4% (w/v) SDS 
pH 6.8 
Stripping Buffer 
200 mM Glycine 
0.1% (w/v) SDS 
1% (v/v) Tween-20 
pH 2.2 
TBS-T Buffer 
20 mM Tris-HCL, pH 7.6 
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137 mM NaCl 
0.05% (v/v) Tween-20 
TE Buffer 
10 mM Tris Base 
1 mM EDTA 
 
Table 2-9: Used media 
Medium Formulation Manufacturer 
Complete RPMI RPMI 1640 
10% (v/v) FCS 
1%  (v/v) Pen/Strep 
Invitrogen (Darmstadt) 
Gibco (Eggenstein) 
Invitrogen (Darmstadt) 
Cell medium for microscopy RPMI 1640, no Phenol Red 
10% (v/v) FCS  
Invitrogen (Darmstadt) 
Gibco (Eggenstein) 
LB medium 2% (w/v) LB-Broth (Lennox) 
Roth (Karlsruhe) 
 
2.1.9 Prokaryotic cells 
Table 2-10: Used bacteria 
Bacterial strain Description Manufacturer 
E. coli DH5 α  
 
deoR endA1 hsdR17 (rk-, mk+) supE44 
thi-1 recA1  ∆(argFV169-LacZYA) U169 
Φ80lacZ∆M15 F- λ- 
Invitrogen (Darmstadt) 
  MATERIALS AND METHODS 
24 
 
2.2 Methods 
2.2.1 Animal studies 
2.2.1.1 Generation of transgenic mice 
Transgenic mice are widely used in laboratory research carried out to elucidate the 
physiological functions of gene products and their implications in human diseases. 
For the generation of transgenic mice two different vectors were cloned as described in 
2.2.4.10. All further processes were carried out in the animal facility of Universitätsklinikum 
Aachen, Pauwelsstr. 30. Briefly, DNA was directly injected into the pronuclei of fertilized 
oocytes. These oocytes were then implanted into the ovary ducts of pseudo-pregnant mice. 
Genomic DNA was isolated from tails of the offspring and transgenic integration was 
confirmed by PCR (2.2.4.8). 
2.2.1.2 Laboratory animals 
Table 2-11: Used mice 
Name Genetic  
background 
Age Genetic properties 
gp130-wt B6-Mix 8-16 Overexpression of gp130 in the haematopoetic 
compartment under control of the vav 
promoter. Control mice for gp130-mut. 
gp130-mut B6-Mix 8-16 Overexpression of a mutated version of gp130 
in the haematopoetic compartment under 
control of the vav promoter: Serine 778 and 
780 were exchanged for alanine residues to 
produce a non-phosphorylatable mutant, which 
might be impaired in its internalization. 
Wt B6 8-16 Wildtype mice without genetic modification. 
 
All animals were housed in temperature-controlled rooms on a 12-hour light/dark cycle in the 
animal facility of Universitätsklinikum Aachen, Pauwelsstr. 30. Standard diet and water were 
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given ad libitum. All animal experiments were conducted in agreement with German animal 
protection law and were approved by the local animal care committee (file reference: 
50.203.2 AC; 8.87-50.10.35.09.035). 
2.2.1.3 DSS induced chronic colitis 
The oral administration of dextran sodium sulphate (DSS) is a well-established model for the 
induction of colitis, which shows several similarities to human IBD. Inflammation is usually 
restricted to the colon and clinical symptoms include diarrhea, weight loss and occult blood in 
stools. Depending on the DSS concentration, frequency and duration of its administration 
colitis can be developed in an acute or chronic manner (Solomon et al., 2010). Mice were fed 
with 2.5% (w/v) DSS in their drinking water for 1 week followed by 1 week without DSS. 
These cycles were repeated until day 37, when the animals were sacrificed. Control mice 
were included, which were fed with normal drinking water throughout the experiment. Weight 
of the animals was determined every other day. 
2.2.1.4 Zymosan induced peritonitis 
The intraperitoneal (i.p.) injection of zymosan is a well-established model to study the 
infiltration of leukocytes into the peritoneal cavity. Zymosan is a polysaccharide cell wall 
component from Saccharomyces cerevisiae and its injection results in self-resolving acute 
inflammation (Cash et al., 2009). 
 
2.2.2 Immunological methods 
2.2.2.1 Isolation of PBMCs from peripheral blood 
PBMCs were isolated from buffy coats, provided by the local blood bank 
(Transfusionsmedizin, UK Aachen, Germany), or from peripheral blood obtained from healthy 
volunteers. The blood was diluted with PBS at a ratio of 1:1 and layered onto 14 ml of Ficoll 
Histopaque. After centrifugation (950 g, 15 min, RT, without brake in a swing-out rotor) 
mononuclear cells were separated from plasma and erythrocytes. PBMCs formed a distinct 
layer at the plasma-interface and could be transferred with a Pasteur pipette into a new tube. 
The cells were washed two times, counted in a Neubauer haemocytometer and used for 
further analysis. 
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2.2.2.2 Isolation of monocytes from peripheral blood 
For the isolation of monocytes, PBMCs were prepared from peripheral blood as described 
under 2.2.2.1. The separation of monocytes from lymphocytes was performed according to 
Repnik et al. with two different Percoll gradients (Repnik et al., 2003). In the first step 
monocytes were separated from lymphocytes by hyperosmotic Percoll density gradient 
centrifugation (580 g, 15 min, RT, without brake in a swing-out rotor). In the second step, 
dead cells and thrombocytes were removed from monocytes by an isosmotic Percoll density 
gradient centrifugation (350 g, 15 min, RT, without brake in a swing-out rotor). After gradient 
centrifugations cells were washed and counted. The final purity of monocytes was examined 
by flow cytometry (2.2.2.4). 
2.2.2.3 Isolation of cells from spleen and lymph nodes 
Mice were sacrificed by CO2 inhalation and cervical dislocation and the spleen and lymph 
nodes were removed. Organs were collected in tubes containing T cell medium. To prepare 
a single cell suspension, organs were meshed through a 50 µm cell strainer with the stamp 
of a syringe. Red blood cells were lysed with erythrocyte lysis buffer according to the 
manufacturer’s instructions. Cell number was defined with a Neubauer haemocytometer. 
2.2.2.4 Flow cytometry 
Flow cytometry is a laser-based technology, which allows the analysis of multiple parameters 
of individual cells. Single cell suspensions are hydrodynamically focused within a flowing 
sheath fluid before they pass by a laser beam. The scatter light produced by a single cell as 
it passes through the laser beam is collected by different detectors. While forward scatter 
(FSC) gives information about the size, side scatter (SSC) determines the granularity of the 
cell. In addition to these parameters, different lasers can excite a range of fluorophores and 
the emitted light is received by detectors. Fluorophore-labeled antibodies against cell surface 
molecules or intracellular proteins are useful tools to study individual cellular characteristics 
within a heterogeneous population. 
Flow cytometric analysis was performed on BD FACS Canto II (BD Biosciences), while data 
was evaluated usind FCS Express or Flowing Software. Isotype controls or unstained 
samples were used for the determination of quadrants within dot plots. 
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2.2.2.4.1 Detection of cell surface proteins 
5 x 105 to 1 x 106 cells were incubated with fluorescent dye-coupled antibodies against 
specific cell surface epitopes for 20 min on ice. After washing with FACS buffer, cells were 
subjected to analysis. 
2.2.2.4.2 Detection of intracellular phospho-proteins 
1 x 106 cells were fixed in 1.5% (w/v) paraformaldehyde (PFA) for 10 min at RT. After 
centrifugation, cells were resuspended in 1 ml ice-cold methanol and either incubated on ice 
for 10 min or stored at -20°C for up to 3 days. Cells were washed two times with FACS-buffer 
and incubated with antibodies against specific phosphorylated proteins and against cell 
surface epitopes for 30 min at RT. Cells were washed and analyzed. 
2.2.2.4.3 Flow cytometric analyses from whole blood 
A minimum sample of 40 µl was washed once with the same volume of PBS. 1 volume of 
2% (w/v) PFA was added and incubated for 15 min at RT. After washing, the pellet was 
resuspended in 1 ml of erythrocyte lysis buffer and incubated for 15 min at RT. Cells were 
washed and either cell surface staining was performed and continued as described in 
2.2.2.4.1 or 1 ml ice-cold methanol was added and continued as described in 2.2.2.4.2. 
2.2.2.5 Confocal fluorescence microscopy 
Confocal microscopy was performed on Opera High Content Screening System 
(PerkinElmer). This automated system allows fast confocal imaging of cell samples. 
Temperature and CO2 control units enable live cell experiments to be carried out under 
physiological conditions.  
1500 PBMCs per well were seeded onto poly-L-lysine coated 96-well plates and left to settle 
down ON. Non-adhered lymphocytes were removed by washing with PBS and the cells were 
incubated with fluorophore-coupled antibodies for 30 min on ice. Cells were washed with 
PBS to remove non-bound antibody and cell medium for microscopy with or without IL-1β 
was added prior to microscopy. 
Images were acquired automatically from 10 positions per well and using a 40x air objective. 
The images were blinded and cells assessed based on the following scoring system:  
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Table 2-12: Internalization score 
Score Description 
0 No internalization: staining localized only at the membrane 
0.5 Early internalization: appearance of some rafts 
1 Medium internalization: appearance of many rafts 
1.5 Late internalization: appearance of many rafts and intracellular staining 
 
 
2.2.3 Proteinchemical methods 
2.2.3.1 Preparation of cell lysates 
4 to 5 x 106 cells were lysed in 200 µl of RIPA buffer containing protease-inhibitors (complete 
mini). Lysates were incubated on ice for 15 min. For homogenization and to shear the high 
molecular weight DNA, lysates were passed 15 to 20 times through a 19G needle attached 
to a 1 ml syringe. Cell debris was pelleted at 17000 x g for 20 min at 4°C and the supernatant 
transferred to a new Eppendorf tube. Clarified lysates were subjected to further analysis or 
stored at -20°C. 
2.2.3.2 Bradford 
For the determination of protein concentrations the classic method of Bradford (Bradford, 
1976) was used. 2 µl of clarified cell lysates were mixed with 798 µl dd H2O and 200 µl of 
Bradford reagent. Following 10 min of incubation at RT, absorption at 595 nm was measured 
and the protein concentration calculated based on a calibration line generated for BSA. 
2.2.3.3 SDS-polyacrylamide gelelectrophoresis (SDS-PAGE) 
The denaturing SDS-PAGE allows the separation of proteins according to their molecular 
weight. The anionic detergent SDS binds quantitatively to the linearized protein and 
generates a negative net charge. During their electrophoretically driven movement towards 
the anode through a polyacrylamide gelmatrix the proteins are separated. 
  MATERIALS AND METHODS 
29 
 
The discontinuous SDS-PAGE was performed according to Laemmli (Laemmli, 1970) with a 
5% stacking gel and a 7.5-12% separating gel. A prestained protein ladder served as 
molecular marker for the determination of protein size. The electrophoresis was carried out at 
150 V.  
2.2.3.4 Western blot and immunodetection 
Proteins separated by SDS-PAGE were transferred to a polyvinylidene difluoride (PVDF) 
membrane in an electrophoretic semi-dry blotting chamber. After transfer the membrane was 
incubated with blocking buffer for 45 to 60 min at RT. For the immunodetection of specific 
proteins the membrane was incubated with a suitable antibody at 4°C ON. After several 
wash steps a secondary, HRP-coupled antibody, which binds to the primary antibody was 
added for 45 to 60 min at RT. Following another 3 to 5 washes the membrane was incubated 
with ECL solution, containing an HRP-substrate. Under emission of chemiluminescence this 
substrate is turned over by the enzyme and the signal can be detected with a computer-
assisted camera system (LAS4000, Fuji). 
2.2.3.5 Immunoprecipitation 
By the use of an antibody against a specific protein of interest, an immunoprecipitation can 
serve to concentrate this protein in a cellular extract. Protein-G coupled beads bind to the 
antibody-protein complex and can subsequently be isolated from the lysate. The precipitated 
protein is detected in a western blot. 
4 x 107 monocytes with a minimum purity of 70% were lysed in 500 µl RIPA buffer containing 
protease inhibitors. Protein concentration of clarified lysates (2.2.3.1) was measured by 
Bradford (2.2.3.2) and 2 to 2.5 mg of protein were incubated with 1 µg of antibody at 4°C ON. 
After addition of protein G coupled beads samples were incubated for another 4 hours at 
4°C. Immune complexes were washed, mixed with 10 µl of 2x sample buffer and boiled for 
5 min at 96°C followed by SDS PAGE and western blot. 
2.2.3.6 Blot stripping 
The treatment of PVDF membranes, which have already been subjected to 
immunodetection, with stripping buffer allows a new incubation with antibodies and detection 
of another protein of interest.  
For stripping of antibodies the membrane was incubated with stripping buffer for 30 min. The 
solution was then changed, followed by another 30 min incubation. The membrane was 
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washed several times and the blocking step was repeated before the treatment with the 
suitable antibody and immunodetection (2.2.3.4). 
 
2.2.4 Work with nucleic acids 
2.2.4.1 DNA preparation 
DNA was extracted from transformed bacteria according to the manufacturer’s instructions 
using the NucleoBond® PC500 kit (Macherey-Nagel) for preparative purposes and the Zippy 
Plasmid Miniprepkit (Zymo Research) for small-scale preparations. 
2.2.4.2 RNA preparation 
Total RNA was extracted from primary cells using the RNeasy Mini Kit (Qiagen) following the 
manufacturer’s instructions.  
2.2.4.3 cDNA synthesis 
Extracted RNA was transcribed to cDNA using the First Strand cDNA Synthesis Kit 
(Fermentas) according to the manufacturer’s instructions. 
2.2.4.4 Enzymatic manipulation of plasmid DNA 
Plasmid DNA was digested in 25 µl reaction volume using restriction enzymes (Fermentas) 
with appropriate buffers for 1 h to overnight at the denoted temperature. 
DNA was ligated using T4 Ligase (Fermentas). Sticky end ligations were carried out for 1 to 
2 h at RT, blunt end ligations ON at 16°C. 
2.2.4.5 Determination of concentration and purity of DNA and RNA 
The concentration of DNA and RNA was measured on a photospectrometer where the 
absorption of the nucleic acid at 260 nm was determined. The purity was determined by the 
ratio OD260 nm/OD280 nm.  
2.2.4.6 Agarose gel electrophoresis 
The electrophoretic separation of DNA fragments was performed as described (Sambrook et 
al., 1989) in 0.5-2% (w/v) agarose gels. 
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2.2.4.7 Gel extraction 
DNA was recovered from agarose gels using the Wizard SV Gel and PCR Clean-Up System 
(Promega) according to the manufacturer’s instructions.  
2.2.4.8 Polymerase chain reaction (PCR) 
For the enzymatic amplification of DNA fragments suitable primers were used, which flanked 
the respective regions.  
For PCR reactions with analytical purposes TopTaq DNA Polymerase (Qiagen) was used, 
while for reactions where the products were to be further utilized for cloning Phusion 
Polymerase (Finnzymes) was used. 
2.2.4.9 Quantitative real time polymerase chain reaction (RT-PCR) 
As with the conventional PCR reaction in quantitative real time PCR, specific nucleic acid 
fragments are amplified with the help of oligonucleotides flanking the suitable regions. The 
use of DNA intercalating fluorescent dyes or labeled probes allows the additional 
quantification of the generated products. In each cycle the increase of fluorescence is 
measured, which rises in proportion to the number of PCR-products. The cycle threshold (ct)-
value describes the cycle where the number of copies rises exponentially and was used for 
analysis of the results.  
Quantitative RT-PCR was carried out on a TaqMan 7900 (Applied Biosystems) using the 
intercalating dye SYBR green, included in the quantitative RT-PCR Master Mix for SYBR 
Green I (Eurogentec GmbH). 7000 System SDS Software was used for data evaluation. 
Housekeeping genes were analyzed for normalization and calculation of relative expression. 
2.2.4.10 Cloning 
Cloning of the vectors for gp130 transgenic mice was performed according to Ogilvy et al. 
(Ogilvy et al., 1999). The vav haematopoetic vector was digested with the restriction 
enzymes SfiI and NotI to remove the hCD4 sequences. PCR products with appropriate SfiI 
and NotI specific overhangs were generated from SW213 and SW214, kindly provided by the 
Department of Biochemistry (UK Aachen). After digestion of the PCR products, they were 
subcloned into the vav haematopoetic vector.  
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2.2.4.11 Sequencing 
All cloned vectors were controlled by sequencing (Eurofins MWG). Samples were prepared 
according to the sample submission guide of the company. 
 
2.2.5 Work with prokaryotic cells 
2.2.5.1 Transformation 
100 µl competent bacteria (E. coli DH5α) were thawed on ice and mixed with 50-500 ng 
plasmid DNA. After up to 30 min incubation on ice, bacteria were subjected to heat-shock for 
45 sec at 42°C and immediately placed back on ice. 900 µl of LB medium were added and 
the tube was incubated for 1 h at 37°C. Bacteria were pelleted by centrifugation, 
resuspended in 100 µl of LB medium and plated on LB agar plates containing the appropriate 
antibiotics. Plates were incubated ON at 37°C.  
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3 RESULTS 
3.1 Crosstalk inhibition of IL-6 signaling in human monocytes 
3.1.1 Effect of IL-1β on gp130 surface expression 
Previous studies with hepatocytes have shown a crosstalk inhibition of IL-6 signaling by pro-
inflammatory cytokines and stress stimuli. This inhibition was mediated by phosphorylation 
and subsequent internalization and degradation of the IL-6 receptor subunit gp130 (Radtke 
et al., 2010). Other groups demonstrated a negative influence of pro-inflammatory cytokines 
on STAT3 phosphorylation, also in other cell types such as macrophages, but the precise 
mechanism remained unclear (Ahmed and Ivashkiv, 2000). 
Since IL-6 signaling plays a major role in different immune reactions and is implicated in the 
pathogenesis of chronic inflammatory disorders, we decided to investigate whether the 
mechanism discovered in hepatocytes can be found in immune cells as well.  
In human peripheral blood almost all monocytes display a high expression of gp130 (Oberg 
et al., 2006). As shown in figure 3-1, these observations could be confirmed by our own flow 
cytometric analyses. PBMCs were isolated from healthy donors and stained for gp130 and 
the monocyte marker CD14. The gate was set to CD14+ cells and gp130 expression within 
the monocyte population was analyzed. Approximately 95% of the monocytes displayed cell 
surface expression of gp130.  
 
Figure 3-1: Cell surface expression of gp130 on monocytes.  
FACS analysis (2.2.2.4.1) of human PBMCs. Cells were isolated and incubated with antibodies 
against CD14 and gp130. The gate was set on CD14
+
 cells (left dotplot) and monocytes were 
classified as gp130
-
 or gp130
+
 based on isotype control. Representative plots are shown.  
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We therefore focused on this population and performed live-cell imaging to investigate the 
influence of IL-1β on gp130 surface expression. After isolation PBMCs were allowed to settle 
down. A reduction of lymphocytes and an enrichment of adherent monocytes was achieved 
by washing the cells stringently. The cells were labeled with antibodies against gp130 and 
CD14 and analyzed by confocal fluorescence microscopy. Figure 3-2 A shows representative 
images of cells left untreated (upper panel) compared to samples stimulated with 
recombinant IL-1β (lower panel). Pictures were taken immediately after subjecting the 
samples to microscopy and every 10 min. While a localization of the gp130-staining could be 
detected mainly at the cell membrane in untreated cells, monocytes exhibited less clear 
membrane staining in the presence of IL-1β. Instead, gp130 was distributed throughout the 
cell and some rafts were visible (see arrowheads). In figure 3-2 B a statistical analysis of two 
individual microscopy experiments can be seen. According to the degree of internalization, 
cells were assessed based on a scoring system (table 2-12). There was a certain rate of 
constitutive internalization during the experiment, which explains how the internalization 
score had reached almost 0.5 at time point 2 min and rose further even in the absence of 
IL-1β. However, in the presence of IL-1β internalization was significantly higher compared to 
untreated cells. 
To confirm these findings, gp130 surface expression was measured by flow cytometry after 
stimulation with IL-1β and compared to non-stimulated cells. PBMCs were gated on CD14+ 
cells and mean fluorescence intensity (MFI) of gp130 within the monocyte population was 
examined. Figure 3-2 C shows a small but reproducible downregulation of gp130 surface 
expression after 20 min of stimulation with IL-1β. 
  RESULTS 
35 
 
 
Figure 3-2: Effect of IL-1β on gp130 cell surface expression on CD14
+
 human monocytes. 
A) Confocal fluorescence microscopy (2.2.2.5). PBMCs were labeled with α-gp130-FITC and α-CD14-
APC for 30 min on ice. Medium with or without IL-1β (20 ng/ml) was added to the cells after washing 
and the plate was subjected immediately to live-cell imaging at 37°C. 10 pictures per well were taken 
every 10 min. Representative images are shown. B) Statistical analysis of microscopy (based on table 
2-12). Bars represent mean values plus SEM (n = 231 for untreated, n = 61 or n = 46 for treated cells); 
*** p<0.001 (one-way ANOVA with Dunn’s Multiple Comparison Test). C) FACS analysis (2.2.2.4.1) of 
human PBMCs. Cells were stimulated with IL-1β (20 ng/ml) for 20 min and gp130 expression on the 
cell surface was determined by FACS analysis. CD14 was co-stained and 5000 CD14
+
 cells were 
recorded. MFI values measured for untreated cells were set to 1. Horizontal lines represent mean 
values plus SEM (n=11); *** p<0.001 (one sample t-test). 
 
In summary, the pro-inflammatory stimulus IL-1β had a significant influence on gp130 
surface expression on human monocytes. Enhanced internalization of the receptor was 
observed within minutes of stimulation. While the internalization score, determined by 
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confocal microscopy, rose by more than 60%, gp130 cell surface expression, measured by 
flow cytometry, was reduced by approximately 10%.  
3.1.2 Influence of IL-1β on STAT3 activation 
As a consequence of diminished gp130 expression on the cell surface downstream signaling 
was assumed to be affected. To test this hypothesis, PBMCs were stimulated with IL-1β or 
left untreated before IL-6 was added for different periods of time. Cells were lysed and 
phosphorylation of STAT3 was detected in a western blot. Figure 3-3 A shows a clear 
induction of p-STAT3 after stimulation with IL-6 for 10 or 30 min. Pre-incubation of the cells 
with IL-1β for 15 min resulted in a reduction of phosphorylated protein. The amount of non-
phosphorylated STAT3 remained constant as illustrated in the lower panel. Flow cytometric 
analyses confirmed an inhibitory effect of IL-1β on IL-6-induced STAT3 phosphorylation, as 
demonstrated in figure 3-3 B. Cells were stimulated as described for A and based on the 
surface marker CD14 only the MFI of monocytes is shown in the representative histogram. 
Basal STAT3 phosphorylation of non-stimulated cells is shown in black. The red line 
indicates STAT3 activation induced by IL-6 while the blue histogram represents MFI of 
p-STAT3 after pre-incubation with IL-1β and subsequent IL-6 stimulation. Although pre-
incubation with IL-1β did not reduce STAT3 phosphorylation to baseline level, a clear 
reduction could be monitored. To exclude the possibility that the observed effects on STAT3 
activation were mediated by co-stimulation of other cell types contained in PBMCs, 
monocytes were purified from PBMCs by gradient density centrifugation. Isolated monocytes 
with a minimum purity of 70%, as determined by flow cytometry, were stimulated in the same 
manner as described for PBMCs. Figure 3-3 C shows histograms of p-STAT3 MFI, 
analogous to figure 3-3 B. As illustrated by the histograms, inhibition of IL-6-mediated STAT3 
phosphorylation by IL-1β was comparable in isolated monocytes to PBMCs. 
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Figure 3-3: STAT3 phosphorylation after stimulation with IL-1β.  
A) Western Blot (2.2.3.4) of PBMCs. 3 x 10
6
 cells were stimulated with IL-6 (20 ng/ml) for the indicated 
times. For co-stimulation IL-1β (20 ng/ml) was added 15 min prior to the addition of IL-6. Cells were 
lysed and separated in a 12% SDS-PAGE (2.2.3.3). Phosphorylated STAT3 was detected in a western 
blot, membrane was stripped (2.2.3.6) and re-probed with an antibody against STAT3. Quantification 
of protein amounts is shown as ratio of p-STAT3:STAT3. Ratios of untreated cells were set to 1. 
B) and C) Flow cytometric analysis of STAT3 phosphorylation (2.2.2.4.2). 1 x 10
6 
PBMCs (B) or 
monocytes (C) were stimulated as described in A. After 10 min of IL-6 stimulation, cells were fixed, 
lysed and stained for p-STAT3. CD14 was co-stained and 5000 CD14
+
 cells were recorded. 
Histograms show MFI for p-STAT3 within the CD14
+
 population. A filled histogram illustrates untreated 
cells as a control, the red line represents MFI after IL-6 stimulation and the blue line after 
co-stimulation with IL-1β. One representative experiment out of 5 is shown. 
As demonstrated by different approaches, IL-1β diminished STAT3 phosphorylation 
mediated by IL-6. To clarify that this effect was not a result of IL-6-induced feedback 
inhibition, the influence of SOCS proteins was investigated by two different methods. Figure 
3-4 A shows that the addition of actinomycin D, an inhibitor of protein synthesis and thus of 
SOCS expression, had no impact on IL-1β-mediated reduction of STAT3 phosphorylation 
after IL-6 stimulation. The pre-incubation of PBMC cultures with IL-1β led to decreased levels 
of p-STAT3 in response to IL-6, independent of de novo protein synthesis. A more specific 
verification was carried out by quantitative RT-PCR where the expression level of SOCS3 
was determined after addition of IL-1β, IL-6, or a combination of both cytokines. The 
incubation of PBMCs with IL-6 for 1 h was used as positive control and revealed a clear 
induction of SOCS3 expression compared to the untreated sample, as shown in figure 3-4 B. 
  RESULTS 
38 
 
A slight increase of SOCS3 expression could be noted after IL-6 stimulation for 10 min. This 
was not further enhanced by pre-treatment of IL-1β nor did IL-1β alone lead to a significant 
induction of SOCS3 compared to untreated cells. 
 
Figure 3-4: Influence of SOCS on IL-1β-mediated inhibition of STAT3 phosphorylation.  
A) FACS analysis of STAT3 phosphorylation (2.2.2.4.2). After incubation with actinomycin D (5 µg/ml) 
or the carrier DMSO for 30 min, PBMCs were stimulated with IL-6 (20 ng/ml) for 10 min. For co-
stimulation IL-1β (20 ng/ml) was added 20 min prior to the addition of IL-6. Cells were fixed and 
permeabilized followed by the incubation with antibodies against p-STAT3 and CD14. FACS analysis 
was performed and 5000 CD14
+
 cells were recorded. MFI of p-STAT3 within the CD14
+
 population 
was used for statistical analysis and values measured for IL-6-treated cells, pre-incubated with DMSO, 
were set to 1. Bars represent mean values plus SEM (n = 5); ns = not significant; *** p<0.001 (one-
way ANOVA with Bonferroni‘s Multiple Comparison Test). B) Quantitative RT-PCR (2.2.4.9). PBMCs 
were incubated with IL-6 (20 ng/ml) for 1 h as positive control, or for 10 min. IL-1β (20 ng/ml) was 
added 20 min prior to IL-6 for co-stimulation. RNA was isolated (2.2.4.2) and transcribed to cDNA 
(2.2.4.3) before being used for quantitative RT-PCR. The expression of SOCS3 was adjusted to 
expression of the housekeeping gene RPL and values for untreated cells were set to 1. Bars represent 
mean values of n-fold SOCS3 expression plus SEM (n = 4); ns = not significant (one-way ANOVA with 
Bonferroni‘s Multiple Comparison Test). 
Taken together, the results show that IL-1β exerted an inhibitory effect on IL-6-induced 
STAT3 activation. This effect was independent of protein synthesis and thus of the feedback 
inhibitor SOCS3. 
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3.1.3 The role of p38 in crosstalk inhibition of IL-6 signaling 
It has been described earlier that feedback inhibition in hepatocytes and macrophages 
depends on the MAPK p38 (Ahmed and Ivashkiv, 2000; Radtke et al., 2010). We therefore 
investigated the role of p38 in our model. First of all, the induction of p38 phosphorylation by 
IL-1β was tested by flow cytometry after different periods of time. CD14 was co-stained and 
the MFI for p-p38 within the monocyte population was determined. As shown by the black 
histogram in figure 3-5, p38 was activated after 10 min of IL-1β stimulation. At the 20 min 
time point the amount of phosphorylated p38 was slightly decreased again and after 30 min it 
had almost reached baseline levels. Barely any p-p38 was measurable after 45 min of 
stimulation.  
 
Figure 3-5: Activation of p38 after IL-1β stimulation.  
FACS analysis of p38 phosphorylation (2.2.2.4.2). PBMCs were incubated with IL-1β (20 ng/ml) for 10, 
20, 30 or 45 min, fixed, permeabilized and incubated with antibodies against p-p38 and CD14. 5000 
CD14
+
 cells were recorded and expression of p-p38 within the monocyte population is shown. Filled 
histograms represent MFI of untreated cells, black lines of stimulated cells. One representative 
experiment out of 3 is shown.   
In the next experiments, the influence of a p38-specific inhibitor on gp130 surface expression 
and IL-6-induced STAT3 phosphorylation after IL-1β treatment was examined by flow 
cytometry. PBMCs were incubated with IL-1β in the presence or absence of the p38 inhibitor 
SB202190 and gp130 expression on CD14+ cells was measured. Figure 3-6 A shows that 
inhibition of p38 rescued the decreased gp130 expression after stimulation with IL-1β. To 
investigate whether this restored cell surface expression was reflected in the level of STAT3 
phosphorylation, PBMCs were stimulated with IL-1β or left untreated before the addition of 
IL-6. Duplicates of each sample were prepared and pre-stimulated with SB202190 or DMSO 
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as control, respectively. As indicated by figure 3-6 B, IL-6-induced STAT3 phosphorylation 
was reduced by IL-1β in DMSO-treated cells by approximately 60%. However, in cells 
stimulated with SB202190 the inhibitory effect of IL-1β was absent. 
 
Figure 3-6: Influence of SB202190 on crosstalk inhibition by IL-1β.  
A) FACS analysis of cell surface gp130 expression (2.2.2.4.1). After incubation with SB202190 (1 µM) 
or DMSO for 30 min, PBMCs were stimulated with IL-1β (20 ng/ml) for 20 min or left untreated. 
PBMCs were stained with antibodies against gp130 and CD14 and 5000 CD14
+
 cells were recorded. 
MFI values of untreated monocytes were set to 1. Symbols indicate individual values and horizontal 
lines represent mean plus SEM (n = 6); ** p<0.01 (two-tailed, paired t-test). B) FACS analysis of 
p-STAT3 (2.2.2.4.2). PBMCs were pre-treated with SB202190 (1 µM) or DMSO for 30 min followed by 
stimulation with IL-6 (20 ng/ml) for 10 min. For co-stimulation IL-1β (20 ng/ml) was added 20 min prior 
to the addition of IL-6. Cells were fixed and permeabilized followed by the incubation with antibodies 
against p-STAT3 and CD14. FACS analysis was performed and 5000 CD14
+
 cells were recorded. MFI 
of p-STAT3 within the CD14
+
 population is shown and values measured for DMSO- and IL-6-treated 
cells were set to 1. Bars represent mean values plus SEM (n = 5); *** p<0.001 (one-way ANOVA with 
Bonferroni‘s Multiple Comparison Test). 
3.1.4 Influence of IL-1β on phosphorylation of serine 782 
Different studies have shown that the internalization of gp130 is dependent on a di-leucine 
motif within its cytoplasmic domain (Dittrich et al., 1994). It was suggested that serine 782, 
located in close proximity to the di-leucine motif, serves as a stress sensor, regulating the 
internalization process and thus the availability of gp130 on the cell surface (Gibson et al., 
2000; Radtke et al., 2010). Phosphorylation of this residue was therefore examined in 
response to IL-1β in monocytes. PBMCs were derived from human blood and monocytes 
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were isolated from PBMCs. Monocytes were at least 70% pure, as determined by FACS 
analysis shown in figure 3-7 A. Cells were stimulated with IL-1β or left untreated and this was 
followed by cell lysis and immunoprecipitation of gp130. Phosphorylation of serine 782 was 
detected in a western blot, illustrated by figure 3-7 B. After stimulation with IL-1β a slightly 
stronger phosphorylation was observed compared to untreated cells. The blot was stripped 
and re-probed with an antibody against gp130 to exclude the possibility that the total amount 
of gp130 differed between treated and non-treated cells. As the lower panel illustrates, the 
quantity of gp130 was unaffected. 
 
Figure 3-7: Phosphorylation of serine 782 after IL-1β treatment.  
A) Monocytes were isolated (2.2.2.2) and properties of size and granularity were analyzed by FACS 
analysis. The gating for this population of monocytes was based on their well-characterized size and 
granularity. B) Immunoprecipitation (2.2.3.5). Monocytes (purity 70-80%) were stimulated with IL-1β 
(20 ng/ml) for 20 min or left untreated. Cells were lysed with RIPA buffer and clarified lysates or RIPA 
buffer alone were incubated with α-gp130 and protein G beads. Serine phosphorylation of 
immunoprecipitated gp130 was monitored by immunoblotting. The blot was stripped and re-probed 
with an antibody against gp130 to ensure equal loading. One representative experiment out of 5 is 
shown. Quatification is shown as ratio of phosphorylated:unphosphorylated protein and was set to 1 
for untreated cells. 
Compared to untreated monocytes, phosphorylation of serine 782 in the cytoplasmic tail of 
gp130 was enhanced after stimulation with IL-1β. 
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3.2 In vivo relevance of receptor internalization – a mouse 
model 
To investigate whether the observed crosstalk mechanism in human monocytes is of 
relevance in vivo, we decided to generate transgenic mice with alterations of gp130 serine 
phosphorylation sites. The vav promoter was used to drive overexpression stably throughout 
the hematopoietic compartment. Vav is expressed in all hematopoietic cells but is hardly 
found in other cell types (Ogilvy et al., 1999). According to figure 3-8, two different constructs 
were cloned. In the first one, gp130 wildtype was included (transgenic mice are referred to as 
gp130-wt). This strain was supposed to serve as control for the second mouse line to be 
established where a mutated gp130 was inserted (referred to as gp130-mut).  
 
 
Figure 3-8: Constructs used to establish two trangenic mouse strains.  
HS21/45 vav-hCD4 vector was digested with the restriction enzymes Sfi I and Not I to remove hCD4 
element and insert gp130-wt (A) or gp130-mut (B). 
The mutation changes serine 778 and serine 780 to alanines. These residues, analogous to 
serine 780 and serine 782 in the human receptor (figure 3-9), might be critical for 
internalization in response to stress stimuli. Since alanine prevents phosphorylation, the 
mutation should inhibit potential crosstalk regulation of IL-6 signaling in gp130-mut mice. 
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Figure 3-9: Protein alignment of cytoplasmic fragment of human and murine gp130.  
One letter code for amino acids is shown. Section contains the di-leucine internalization motif in blue 
and the two upstream serine residues are shown in red. 
3.2.1 Determination of gp130 expression and STAT3 phosphorylation 
After generation of the two transgenic mouse lines the animals were analyzed. No 
phenotypic differences were observed in any of them compared to mice without transgene 
(referred to as wt). Quantitative RT-PCR from splenocytes was performed to investigate 
mRNA levels of gp130 in transgenic mice compared to wt mice. As shown in figure 3-10, 
transgenic mice displayed increased levels of gp130 mRNA. Approximately 4-fold levels 
were found in splenocytes of gp130-wt mice, whereas in gp130-mut splenocytes 3-fold levels 
were detected compared to wt mice.  
 
Figure 3-10: Expression of gp130 mRNA in wt and transgenic mice.  
Quantitative RT-PCR (2.2.4.9) of splenocytes. Cells were isolated and RNA was prepared (2.2.4.2). 
After transcription to cDNA (2.2.4.3), quantitative RT-PCR was performed. The expression of gp130 
was adjusted to the housekeeping gene actin. Bars represent n-fold expression of gp130 compared to 
expression level of wt splenocytes, which were set to 1. Bars show mean plus SEM (n = 3). 
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After confirmation that transgenes were present not only at the genomic level, but that also 
enhanced levels of gp130 mRNA could be found in splenocytes of transgenic animals, we 
investigated cell surface expression of gp130 on different hematopoietic cells. Since the aim 
of this mouse model was to find out whether the cell surface expression of gp130 was 
influenced by the mutation of serine 778/780, gp130-mut mice were compared to gp130-wt 
animals. Basal expression was analyzed in peripheral blood (PB) by flow cytometry. As 
shown in figure 3-11 A, gp130-mut animals exhibited significantly lower gp130 expression on 
whole living cells from PB compared to gp130-wt mice. To investigate in which leukocyte 
subset these changes were visible, different markers were co-stained. By gating to these 
populations, gp130 expression was analyzed on CD3+ T cells, CD19+ B cells and CD11b+ 
myeloid cells. Values for gp130-wt mice were set to 1 and the expression on gp130-mut cells 
is shown in figure 3-11 B. Expression of gp130 differed on gp130-mut CD19+ and CD11b+ 
subsets where decreased amounts of the receptor on the cell surface were detected 
compared to gp130-wt cells. This tendency was also visible for T cells, however, the lowest 
expression level of gp130 compared to gp130-wt was determined for B cells.  
 
Figure 3-11: Expression of gp130 on different leukocyte subsets from PB.  
Flow cytometric analysis of cell surface expression from whole blood (2.2.2.4.3). After fixation of cells 
with PFA, erythrocytes were lysed followed by incubation with antibodies against gp130, CD3, CD19 
and CD11b. Gates were set to whole living cells (A), CD3
+
, CD19
+
 or CD11b
+
 cells (B) and MFI of 
gp130 within the particular population was determined. A) Bars represent mean plus SEM (n = 7 for 
gp130-wt, n = 4 for gp130-mut); * p<0.05 (two-tailed, unpaired t-test). B) Values measured for 
gp130-wt splenocytes were set to 1. Boxes show MFI values for gp130 within the indicated cell 
populations from gp130-mut mice. Boxes and whiskers represent values from min to max, horizontal 
line represents mean (n = 7 for gp130-wt, n = 4 for gp130-mut). 
To investigate whether the observed differences were visible on splenocytes as well, the 
same flow cytometric analysis was performed with this cell type. In contrast to PB cells, 
  RESULTS 
45 
 
gp130 expression on whole living splenocytes did not differ between gp130-wt and 
gp130-mut as can be seen in figure 3-12 A. Expression in subpopulations was determined to 
establish whether subtle differences were apparent on T cells, B cells or myeloid cells. Figure 
3-12 shows the expression of gp130 on the indicated cell population isolated from gp130-mut 
in relation to gp130-wt. While slightly reduced expression levels on CD3+ cells could be 
observed, no changes were detected for CD19+ or CD11b+ cells.  
 
 
Figure 3-12: Expression of gp130 on different splenocyte subsets.  
FACS analysis of cell surface expression (2.2.2.4.1). Cells were isolated from spleens and incubated 
with antibodies against gp130, CD3, CD19 and CD11b. Gates were set to whole living cells (A) CD3
+
, 
CD19
+
 or CD11b
+
 (B) and gp130 expression within the different populations was determined as MFI. 
A) Bars represent mean plus SEM (n = 7 for gp130-wt, n = 4 for gp130-mut); ns = not significant (two-
tailed, unpaired t-test). B) Values obtained for gp130-wt were set to 1. Boxes show MFI values for 
gp130 within the indicated cell populations from gp130-mut mice. Boxes and whiskers represent 
values from min to max, horizontal lines represent mean (n = 7 for gp130-wt, n = 4 for gp130-mut). 
For further analyses we decided to use splenocytes, since they are easy to isolate and high 
numbers of cells can be recovered. STAT3 phosphorylation was determined at baseline and 
after stimulation with IL-6. Figure 3-13 A shows the amount of p-STAT3 in splenocytes 
isolated from gp130-mut mice in relation to cells from gp130-wt without any stimulation. MFI 
of p-STAT3 was determined within the indicated subpopulations and values for gp130-wt 
were set to 1. Basal STAT3 activation did not differ significantly in any of the three cell 
populations of gp130-mut mice compared to gp130-wt. However, after IL-6 stimulation 
STAT3 was activated significantly stronger in the T cell population of gp130-mut splenocytes 
compared to gp130-wt, as illustrated in figure 3-13 B. Values relative to basal STAT3 
phosphorylation are shown. From figure 3-13 C and D it can be seen that STAT3 induction 
did not differ between gp130-mut and gp130-wt in CD19+ and CD11b+ cells, respectively.  
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Figure 3-13: Expression of p-STAT3 in different leukocyte subsets from splenocytes.  
FACS analysis of p-STAT3 (2.2.2.4.2). After fixation and permeabilization, cells were incubated with 
antibodies against p-STAT3, CD3, CD19 and CD11b. Gates were set to CD3, CD19 or CD11b and 
MFI values for p-STAT3 within the populations were determined. A) MFI values obtained for gp130-wt 
were set to 1. Boxes and whiskers show values from min to max, horizontal lines represent mean 
(n = 5). B-D) Prior to fixation cells were stimulated with IL-6 (20 ng/ml) for 10 min. MFI values 
measured for untreated cells were set to 1. Horizontal lines represent mean plus SEM (n = 5); ns = not 
significant (two-tailed, unpaired t-test); ** p<0.01 (two-tailed, unpaired t-test). 
Taken together, an increased expression of gp130 mRNA was observed for splenocytes 
from both mouse strains compared to wt animals. On the level of cell surface expression, no 
changes could be detected on different splenocytes subsets, while CD19+ and CD11b+ PB 
cells from gp130-mut mice displayed decreased gp130 surface expression in comparison to 
gp130-wt PB cells. STAT3 phosphorylation in response to IL-6 was stronger in CD3+ 
splenocytes from gp130-mut mice than in those from gp130-wt animals. 
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3.2.2 Influence of IL-1β on gp130 expression and STAT3 activation 
In human monocytes stimulation with IL-1β resulted in downregulation of gp130 surface 
expression and restriction of IL-6-induced STAT3 phosphorylation. These effects depended 
on the MAPK p38 and probably on the phosphorylation of serine 782 within the cytoplasmic 
tail of gp130. Since in the gp130-mut mice the analogous serine residues are mutated to 
alanine and should therefore prevent phosphorylation, in the next experiments the influence 
of IL-1β on gp130 cell surface expression and STAT3 phosphorylation was compared 
between the two mouse strains. Splenocytes were stimulated with IL-1β and gp130 
expression was determined by flow cytometry. Figure 3-14 A shows gp130 expression on the 
surface of whole splenocytes from gp130-mut compared to gp130-wt. Values measured for 
untreated cells were set to 1. After stimulation with IL-1β a slight decrease of gp130 cell 
surface expression on gp130-wt splenocytes was observed, which was not apparent in cells 
from gp130-mut mice. To investigate whether this tendency was more pronounced within one 
distinct cell population, gp130 expression was again examined on T cells, B cells and 
myeloid cells after IL-1β stimulation. As can be seen in figure 3-14 B, CD3+ T cells did not 
turn out to be the population that caused the tendency observed for total splenocytes. No 
downregulation of gp130 on T cells was visible after incubation with IL-1β, either in gp130-wt, 
or in gp130-mut T cells. In contrast, on B cells as well as on myeloid cells from gp130-wt 
animals, IL-1β caused a small decrease of gp130 surface expression as shown in figure 
3-14 C and D, respectively. This decrease was, however, not detected in CD19+ or CD11b+ 
splenocyte subsets from gp130-mut mice.
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Figure 3-14: Influence of IL-1β on gp130 surface expression.  
FACS analysis of cell surface expression (2.2.2.4.1). Splenocytes were stimulated with IL-1β 
(20 ng/ml) for 20 min or left untreated prior to staining with antibodies against gp130, CD3, CD19 and 
CD11b. Gates were set to total living cells (A), CD3
+
 (B), CD19
+
 (C) or CD11b
+
 cells (D) and MFI of 
gp130 was determined. Values for untreated cells were set to 1. Horizontal line represents mean plus 
SEM (n = 7 for A and B, n = 6 for C and n = 5 for D); ns = not significant (two-tailed, unpaired t-test), 
* p<0.05 (two-tailed Mann Whitney test for C, two-tailed, unpaired t-test for D). 
To investigate whether the changes of gp130 cell surface expression were reflected in 
downstream signaling, STAT3 phosphorylation was examined. Splenocytes were incubated 
with IL-1β prior to the addition of IL-6 and p-STAT3 was determined by flow cytometry. 
Control cells were stimulated with IL-1β alone. As shown in figure 3-15 A, an incubation with 
IL-1β did not have any influence on basal STAT3 phosphorylation, irrespective of the 
population being considered. Values for untreated cells were set to 1. In figure 3-15 B-D 
IL-6-induced STAT3 activation after pre-treatment with IL-1β is shown in relation to 
stimulation with IL-6 alone. No changes between gp130-wt and –mut could be observed in 
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T cells (figure 3-15 B). STAT3 phosphorylation was marginally reduced in gp130-mut 
compared to gp130-wt B cells (figure 3-15 C). A tendency was also observed for CD11b+ 
splenocytes: IL-6-induced STAT3 activation was decreased in gp130-wt compared to 
gp130-mut, as shown in figure 3-15 D.  
 
Figure 3-15: Influence of IL-1β on IL-6-induced STAT3 phosphorylation.  
FACS analysis of p-STAT3 (2.2.2.4.2). A) Splenocytes were stimulated with IL-1β for 20 min or left 
untreated. Cells were fixed and permeabilized before the incubation with antibodies against p-STAT3, 
CD3, CD19 and CD11b. MFI values for p-STAT3 were determined within the indicated populations. 
Values for untreated cells were set to 1. Black bars represent mean plus SEM for gp130-wt (n = 5), 
grey bars show mean plus SEM for gp130-mut (n = 5). B-D) Splenocytes were stimulated with IL-6 
(20 ng/ml) for 10 min to induce STAT3 phosphorylation. IL-1β (20 ng/ml) was added 20 min prior to 
the addition of IL-6. Cells were fixed and permeabilized before being stained with antibodies against 
p-STAT3, CD3, CD19 and CD11b. MFI of p-STAT3 was determined within gates set to CD3
+
 (B), 
CD19
+
 (C) or CD11b
+
 cells (D). Values measured for cells treated with IL-6 were set to 1. Boxes and 
whiskers show values from min to max, horizontal lines show mean (n = 5); ns = not significant 
(two-tailed, unpaired t-test). 
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In summary, IL-1β induced a slight downregulation of gp130 surface expression on CD19+ 
and CD11b+ splenocyte subsets of gp130-wt mice. This downregulation, however, was not 
observed for the respective leukocyte subsets of gp130-mut mice. This resulted in significant 
differences between the two transgenic mouse strains regarding gp130 downregulation in 
response to IL-1β. T cells were resistant to regulation of gp130 surface expression by IL-1β 
in both mouse strains. This was reflected in the level of downstream signaling inasmuch as 
IL-1β did not have any influence on IL-6-induced STAT3 phosphorylation in T cells of 
gp130-wt or –mut mice. In contrast, the observed downregulation of gp130 on gp130-wt 
B cells in response to IL-1β was not translated to the level of STAT3 phosphorylation. In 
gp130-wt myeloid cells IL-6-induced STAT3 activation was slightly diminished after IL-1β 
stimulation, which was less pronounced in the respective cell population of gp130-mut mice. 
3.2.3 Migration of leukocytes into the peritoneal cavity 
In the human system IL-6 acts as a migration factor in CD14+ monocytes by inducing 
upregulation of adhesion molecules and reorganization of the actin cytoskeleton (Clahsen 
and Schaper, 2008). Moreover, IL-6 knockout mice display impaired migration of leukocytes 
to sites of inflammation and mice deficient in gp130 likewise show reduced migration of 
myeloid cells (Romano et al., 1997; Sander et al., 2008). We therefore used a model of 
zymosan-induced peritonitis in gp130-wt and –mut mice to explore migration of myeloid cells 
into the peritoneal cavity. Animals were injected intraperitoneally with zymosan and cells 
were collected 24 h after injection from the peritoneal cavity. Total cell numbers were 
determined and quantities of myeloid cells were analyzed by flow cytometry. Figure 3-17 
shows that in gp130-mut mice significantly increased cell numbers could be recovered 
compared to gp130-wt mice. Cells positive for the myeloid marker CD11b+ but negative for 
the macrophage marker F4/80, i.e. neutrophils and monocytes, were found in enhanced 
numbers in peritoneal cavities of gp130-mut mice compared to gp130-wt. However, these 
changes were not significant. The quantity of macrophages, which are characterized by 
carrying CD11b and F4/80, was not altered between the two mouse strains. 
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Figure 3-16: Migration of leukocytes into the peritoneal cavity after administration of zymosan. 
Mice were injected i.p. with 1 ml of zymosan and cells from peritoneal cavity were collected by lavage 
24 h later (2.2.1.4). Cell numbers were determined by counting with a Neubauer haemocytometer. 
Subsequently, cells were incubated with antibodies against CD11b and F4/80 and analyzed by flow 
cytometry (2.2.2.4.1). Gates were set to CD11b
+
F4/80
-
 or CD11b
+
F4/80+ and percentages of cells 
within the respective gates were related to the total cell number. Bars show mean plus SEM (n = 6 for 
gp130-wt and n = 3 for gp130-mut); ns = not significant (two-tailed, unpaired t-test), * p<0.05 (two-
tailed, unpaired t-test). 
In gp130-mut mice more cells, and by trends more CD11+F4/80- cells, were collected from 
peritoneal cavities compared to gp130-wt animals. No changes were observed in the 
numbers of macrophages. 
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3.3 Regulation of gp130 signaling in chronic inflammation  
Since IL-6 signaling plays an important role in different inflammatory disorders, we sought to 
examine the regulatory status of gp130 in children suffering from IBD and JIA. Both 
conditions are accompanied by increased serum levels of IL-6, TNF-α and IL-1β. Biologic 
agents have been developed against all these cytokines and are used clinically. Whereas 
some patients respond well, the same treatment is only partly effective if at all in others. 
Biological parameters to indicate responsiveness of patients, toxicity or prognosis are lacking 
and it is therefore difficult to choose a suitable medication (McInnes and Schett, 2011). The 
combined effects of different cytokines in chronic inflammatory situations create a complex 
network, and crosstalk between these cytokines most likely is of high relevance for the 
biological outcome. As cytokine crosstalk had been found to influence the expression of 
gp130 on human monocytes in in vitro experiments, we asked whether gp130 cell surface 
expression might be changed in patients with chronic inflammation and if downstream 
signaling might be altered. 
3.3.1 Inflammatory bowel disease 
3.3.1.1 Pediatric IBD patients 
To investigate whether the cell surface expression of gp130 might be changed during the 
course of IBD, blood was taken from pediatric IBD patients during routine blood withdrawal. 
Blood from healthy donors was obtained as control. Gp130 expression on monocytes was 
compared between healthy controls and IBD patients by FACS analysis. Figure 3-17 A 
shows the gating on CD14high monocytes, exemplified by a representative dot plot. 
Histograms demonstrate upregulation of gp130 expression on monocytes derived from PB of 
IBD patients (lower panel) compared to those from healthy control (upper panel). This 
significant increase in gp130 measured on the cell surface is displayed as scatter plot for a 
total of 21 patients in figure 3-17 B. To examine whether the expression of the complete IL-6 
receptor complex was changed, the level of IL-6R was analyzed on the cell surface of 
monocytes from IBD patients and healthy controls. Expression levels did not differ 
significantly between the two groups, as is clearly visible in figure 3-17 C. 
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Figure 3-17: Cell surface expression of gp130 and IL-6R of PB monocytes from IBD patients 
compared to healthy controls.  
FACS analysis of cell surface expression from whole blood (2.2.2.4.2). Cells were fixed with 
1% (w/v) PFA and erythrocytes were lysed by incubation with lysis buffer prior to staining. Antibodies 
against gp130 and CD14 (A, B) or IL-6R and CD14 (C) were used. The gate was set to CD14
+
 cells. 
A) Representative dot plot and histograms. Dot plot demonstrates gating to monocytes and stacked 
histograms show MFI of gp130 within the monocyte population of a healthy control (upper panel) and 
an IBD patient (lower panel). B) Symbols indicate MFI of gp130 within the monocyte population from 
individual donors and horizontal lines represent mean values plus SEM; *** p<0.001 (two-tailed 
Wilcoxon signed rank test; n = 21). C) Symbols show MFI of IL-6R within the monocyte population 
from individual donors. Horizontal lines represent mean values plus SEM; ns = not significant (two-
tailed Wilcoxon signed rank test; n = 11).  
We next asked whether downstream signaling was affected by the enhanced amount of 
gp130 on the cell surface and investigated STAT3 phosphorylation in PB monocytes of IBD 
patients in comparison to healthy controls. Enhanced STAT3 activation in monocytes of an 
IBD patient compared to a healthy control is shown in figure 3-18 A on the basis of 
representative dot plots. While only about 16% of the monocytes derived from control blood 
are positive for p-STAT3, approximately 54% of the monocytes from IBD blood show 
p-STAT3 staining. Figure 3-18 B illustrates the change of STAT3 activation in monocytes of 
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children with IBD compared to healthy controls summarized for 15 tested individuals. 
Differences are significant with p<0.01. 
 
Figure 3-18: STAT3 phosphorylation in PB monocytes of IBD patients and healthy controls.  
FACS analysis of p-STAT3 from whole blood (2.2.2.4.3). Prior to staining with antibodies against p-
STAT3 and CD14 cells were fixed with 1% (w/v) PFA, erythrocytes were lysed by incubation with lysis 
buffer and permeabilization was achieved by incubation with ice-cold methanol. The gate was set on 
CD14
+
 cells. A) Representative dot plots showing the percentage of p-STAT3 expressing monocytes 
of healthy control (left) and IBD patient (right). Positive and negative cells were distinguished on the 
basis of unstained cells. B) Symbols indicate p-STAT3 MFI within the monocyte population of 
individual donors (n = 15). Horizontal lines represent mean values plus SEM; ** p<0.01 (two-tailed 
Wilcoxon signed rank test).  
The use of biologic agents in the treatment of IBD has emerged as a standard therapeutic 
strategy in combination with conventional drugs. TNF-α plays a pivotal role in IBD and the 
first biological therapeutic agent to become available was a monoclonal antibody against this 
cytokine (Yang et al., 2012). To investigate whether anti-TNF-α therapy had an influence on 
gp130 expression levels and STAT3 activation in monocytes, PB was obtained from children 
with IBD before and after the treatment with the chimeric monoclonal anti-TNF-α antibody 
infliximab. Figure 3-19 A shows a slight, but reproducible, and thus significant 
downregulation of gp130 expression levels after treatment with infliximab. STAT3 activation 
was also significantly reduced after infliximab treatment as illustrated in figure 3-19 B. 
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Figure 3-19: Expression of gp130 and p-STAT3 in monocytes from IBD patients before and after 
treatment with infliximab.  
FACS analysis from whole blood (2.2.2.4.3). A) Prior to staining with antibodies against gp130 and 
CD14 cells were fixed with 1% (w/v) PFA and erythrocytes were lysed. The gate was set to CD14
+
 
cells and MFI of gp130 was determined. Symbols indicate individual patients (n = 8); ** p<0.01 
(two-tailed, paired t-test). B) Cells were fixed with 1% (w/v) PFA, erythrocytes were lysed and 
permeabilization was achieved by incubation with ice-cold methanol. For staining, antibodies against 
p-STAT3 and CD14 were used and MFI of p-STAT3 was determined within CD14
+
 gate. Symbols 
indicate individual patients (n = 8), * p<0.05 (two-tailed, paired t-test). 
Taken together, PB monocytes of children with IBD displayed higher expression levels of 
gp130 and of p-STAT3. The treatment with an anti-TNF-α antibody resulted in a reduction of 
gp130 surface expression and STAT3 activation. 
3.3.1.2 Chronic colitis in mice 
Mouse models of colitis represent immunological models for human IBD. We decided to 
induce chronic colitis in wildtype mice to analyze cell surface expression of gp130 and 
downstream signaling. Colitis mediated by the administration of DSS is independent of T and 
B cells, as it can be established in severe combined immunodeficiency (SCID) mice, where 
these cell types are absent (Axelsson et al., 1996). To focus on innate immune cells such as 
monocytes, DSS colitis was chosen as model and to enhance the similarity to the situation in 
IBD patients the model was applied chronically. For this purpose mice were fed with water 
containing DSS for one week, followed by normal drinking water for another week. These 
cycles were repeated and mice were sacrificed on day 37. Throughout the experiment, the 
weight of the animals was determined every other day. Change of weight from the first day 
was calculated in %. The resulting curve can be seen in figure 3-20 and shows that control 
animals that had not received any DSS, gained weight continuously throughout the duration 
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of the experiment. In contrast, mice with DSS added to their drinking water lost weight after 
each cycle of DSS. At the end of the 37 days they weighed approximately 8% more than on 
the first day in comparison to control animals, that gained about 22% of weight.  
 
Figure 3-20: Change of weight during chronic colitis.  
One group of wildtype mice (n = 6) was supplied with drinking water containing 2.5% (w/v) DSS for 
one week, followed by normal drinking water for the next week. Cycles were repeated until day 37 to 
induce chronic colitis (2.2.1.3). Another group of wildtype mice (n = 3) served as control and received 
normal drinking water throughout the duration of the experiment. Weight of animals was determined 
every other day and calculated as change in % referred to the weight at the starting day. 
Blood was taken on day 1, before the administration of DSS was started, and on day 37. 
Expression of gp130 and STAT3 phosphorylation was determined by flow cytometry. MFI 
values of the DSS group were referred to MFI of control animals, which was set to 1. 
Expression strength was analyzed within the population of CD11b+ myeloid cells. As 
illustrated in figure 3-21 A, expression of gp130 on CD11b+ cells increased significantly 
during the course of DSS colitis compared to untreated control animals. Figure 3-21 B shows 
that downstream signaling, indicated by STAT3 activation, in this cell population was 
significantly higher on day 37 than on day 1 in comparison to control mice. While on day 1 
the MFI values measured for p-STAT3 were identical to those of control mice, a 1.5-fold 
increase could be determined on day 37 in relation to STAT3 phosphorylation in control 
animals. 
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Figure 3-21: Expression of gp130 and p-STAT3 on day 1 and day 37 of chronic DSS colitis. 
A) FACS analysis of gp130 from whole blood (2.2.2.4.3). Cells were fixed with 1% (w/v) PFA and 
erythrocytes were lysed by the addition of an appropriate lysis buffer. Antibodies against gp130 and 
CD11b were used for staining and samples were subjected to FACS analysis. The gate was set to 
CD11b
+
 cells and MFI values of gp130 were determined. Values measured for control mice were set 
to 1. Boxes and whiskers show values from min to max, horizontal lines represent mean (n = 6 for 
day 1 and n = 5 for day 37); * p<0.05 (two-tailed, paired t-test). B) FACS analysis of p-STAT3 from 
whole blood (2.2.2.4.3). Cells were fixed and erythrocytes lysed as described for A. Cells were 
permeabilized and FACS staining was performed with antibodies against p-STAT3 and CD11b. The 
gate was set to CD11b
+
 cells and values obtained for untreated control animals were set to 1. Boxes 
and whiskers show values from min to max, horizontal lines represent mean (n = 6 for day 1 and n = 5 
for day 37); ** p<0.01 (two-tailed, paired t-test). 
In order to determine whether the changes in gp130 expression and STAT3 activation were 
restricted to PB myeloid cells, mesenteric lymph nodes were prepared from mice on day 37. 
In contrast to the results from PB, the gp130 expression on CD11b+ cells was significantly 
lower in DSS-treated animals as illustrated by figure 3-22 A. It was assumed that the 
downregulation of gp130 would result in a decreased IL-6 responsiveness. This was tested 
by stimulation with IL-6 and the subsequent analysis of STAT3 activation. Figure 3-22 B 
shows that in line with decreased levels of gp130, the potential of CD11b+ cells from DSS-
treated animals to activate STAT3 in response to IL-6 was diminished compared to control 
mice. 
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Figure 3-22: Expression of gp130 and p-STAT3 in CD11b+ cells of mesenteric lymph nodes. 
A) FACS analysis of gp130 expression (2.2.2.4.1) on CD11b
+
 cells isolated from mesenteric lymph 
nodes. Antibodies against gp130 and CD11b were used and the gate was set to CD11b
+
 cells. MFI of 
gp130 within the gate was determined for control animals (black bar) and animals that received DSS 
(grey bar). Bars show mean plus SEM (n = 5); ** p<0.01 (two-tailed Mann Whitney test). B) FACS 
analysis of p-STAT3 (2.2.2.4.2) in cells isolated from mesenteric lymph nodes. Cells were stimulated 
with IL-6 (20 ng/ml) for 15 min prior to staining with antibodies against p-STAT3 and CD11b. MFI of 
p-STAT3 within CD11b
+
 population was determined for control animals (black bar) and DSS-treated 
mice (grey bar). Bars represent mean plus SEM (n = 5); ** p<0.01 (two-tailed, unpaired t-test). 
In summary, the characteristics of PB monocytes from pediatric IBD patients, i.e. increased 
gp130 and p-STAT3 levels, could in part be transferred to a model of chronic colitis in mice. 
After having received DSS for 3 cycles, PB CD11b+ cells of animals displayed higher 
expression of gp130 and p-STAT3 than control mice. However, in mesenteric lymph nodes 
the situation was reversed and decreased gp130 surface expression on CD11b+ cells was 
observed as well as diminished responsiveness to IL-6. 
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3.3.2 Juvenile idiopathic arthritis 
3.3.2.1 Influence of synovial fluid on gp130 and IL-6R expression on monocytes 
To investigate whether the inflammatory situation in the joints of JIA patients influenced the 
expression of the IL-6 receptor complex on monocytic cells, we compared PB monocytes to 
synovial fluid (SF) monocytes. As illustrated by representative histograms in figure 3-23 A, 
both components of the receptor complex were differentially expressed within the two 
compartments. On monocytes from SF (lower panel), significantly lower expression levels of 
gp130 (left) and IL-6R (right) were detected compared to PB monocytes (upper panel). A 
total of 18 and 15 patients were investigated for the expression of gp130 and IL-6R, 
respectively. This is displayed as scatter plots in figure 3-23 B and C. 
 
Figure 3-23: Expression of gp130 and IL-6R on PB and SF monocytes from JIA patients. 
FACS analysis from whole blood and SF (2.2.2.4.3). Cells were fixed with 1% (w/v) PFA followed by 
incubation with lysis buffer to eliminate erythrocytes. FACS staining was performed with antibodies 
against gp130, IL-6R and CD14 and the gate was set to CD14
+
 cells. A) Representative histograms of 
gp130 (left) and IL-6R (right) surface expression within the monocyte population. PB monocytes from 
JIA patient (upper panel) are compared to SF monocytes (lower panel) from the same patient. B) 
Symbols indicate MFI values of gp130 expression of individual patients (n = 18), horizontal lines 
represent mean plus SEM; ** p<0.01 (two-tailed Wilcoxon signed rank test). C) Symbols indicate MFI 
values of IL-6R expression of individual patients (n = 15), horizontal lines represent mean plus SEM; 
*** p<0.001 (two-tailed Wilcoxon signed rank test). 
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In the SF of patients with JIA many pro-inflammatory cytokines can be detected. Since we 
observed a reduction of gp130 surface expression on PB monocytes by the pro-inflammatory 
cytokine IL-1β, we hypothesized that soluble factors present in SF were responsible for the 
observed downregulation of gp130 and IL-6R. Synovial fluid mononuclear cells (SFMCs) 
were isolated from SF by density gradient centrifugation, incubated in RPMI with 
10% (v/v) FCS and rested for up to 60 min. Gp130 and IL-6R expression levels were 
measured after different periods of rest. As shown in figure 3-24 A, the monocytic cell 
surface expression of gp130 increased significantly within 1 hour of culture, whereas IL-6R 
levels remained constant. We thus asked whether incubation with SF would again result in a 
downregulation of gp130 surface expression. We incubated PBMCs, which were isolated 
from healthy donors, with 10% SF in RPMI. As control, cells were stimulated with 
10% (v/v) human serum (HS) in RPMI. MFI of gp130 was measured by flow cytometry and 
values for untreated cells were set to 1. Figure 3-24 B shows that the incubation of PBMCs 
with SF led to a significant downregulation of gp130 surface expression on monocytes. The 
expression of IL-6R after stimulation with SF was determined as well, which is illustrated by 
figure 3-24 C. Although the isolation of SFMCs from SF did not result in an increase of IL-6R 
expression within 1 hour of rest, SF induced downregulation of IL-6R. However, the statistical 
spread of MFI values measured after SF stimulation was much higher than that obtained with 
gp130. 
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Figure 3-24: Effect of SF on IL-6 receptor surface expression.  
FACS analysis (2.2.2.4.1) of SFMCs (A) or PBMCs (B and C). A) Cells were isolated and either 
immediately prepared for FACS analysis or cultured at 37°C and 5% CO2 in RPMI supplemented with 
10% (v/v) FCS for the indicated times prior to flow cytometry. Antibodies against gp130, IL-6R and 
CD14 were used. The gate was set to CD14
+
 cells and MFI values for gp130 (black bars) and IL-6R 
(grey bars) were determined. Bars represent mean values plus SEM (n = 5 for gp130, n = 4 for IL-6R), 
* p<0.05, ** p<0.01, *** p<0.001 (one-way ANOVA with Tukey’s Multiple Comparison Test) B and C) 
PBMCs were isolated and stimulated with 10% (v/v) SF or human serum (HS) as control for 20 min. 
Cells were stained for gp130 and CD14 (B) or IL-6R and CD14 (C) and analyzed by flow cytometry. 
CD14
-
 cells were excluded by gating and untreated controls were set to 1. Symbols indicate MFI of 
paired samples of HS and SF. Horizontal lines represent mean plus SEM (n = 25 for B, n = 18 for C); 
*** p<0.001 (two-tailed Wilcoxon signed rank test), ** p<0.01 (two-tailed paired t-test). 
Previous studies have shown a crosstalk regulation of IL-6 signaling dependent on the 
stress-induced MAPK p38, which was supported by our own findings that the IL-1β-induced 
internalization of gp130 in monocytes was dependent on p38 (figure 3-6 A). We therefore 
asked whether a blockade of p38 would prevent the downregulation of gp130 in PBMCs 
incubated with SF. PBMCs were pre-incubated with the p38-specific inhibitor SB202190 or 
the carrier DMSO, after which SF was added. As shown in figure 3-25 A, cell surface 
expression of gp130 on monocytes could partially be restored by pre-incubation with the p38 
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inhibitor. The same analysis was performed to investigate the effect of SB202190 on 
downregulation of IL-6R by SF. Figure 3-25 shows that inhibition of p38 could partially 
restore diminished expression of IL-6R after SF stimulation. 
 
Figure 3-25: Influence of p38-inhibition on gp130 and IL-6R downregulation by SF.  
Flow cytometric analysis of gp130 (A) or IL-6R (B) surface expression (2.2.2.4.1). PBMCs were 
incubated with DMSO or SB202190 (5 µM) 30 min prior to the addition of SF (10%, v/v) for 20 min. 
A) PBMCs were stained with antibodies against CD14 and gp130. MFI of gp130 measured within the 
CD14
+ 
population for untreated cells was set to 1. Symbols indicate individual values (n = 11); 
* p<0.05 (two-tailed, paired t-test). B) Cells were incubated with antibodies against CD14 and IL-6R. 
CD14
-
 cells were excluded by gating and MFI of IL-6R determined for untreated cells was set to 1. 
Symbols indicate individual values (n = 9); * p<0.05 (two-tailed, paired t-test). 
Taken together, soluble factors in the SF induced downregulation of gp130 and IL-6R 
surface expression on monocytes. This downregulation depended partially on the MAPK 
p38. 
3.3.2.2 Influence of synovial fluid on STAT3 phosphorylation in monocytes 
To investigate whether the downstream signaling in SF monocytes was affected by reduced 
expression levels of gp130 and IL-6R, basal STAT3 phosphorylation was determined and 
compared to PB monocytes. Unexpectedly, SF monocytes displayed significantly higher 
levels of phosphorylated STAT3 than PB monocytes (figure 3-26 A). This led us to analyze 
the IL-6 responsiveness of SF and PB monocytes. Cells were incubated with IL-6 for 15 min, 
fixed, and p-STAT3 levels were determined by flow cytometry. Basal STAT3 phosphorylation 
was set to 1. Figure 3-26 B shows that in PB monocytes of the 4 tested JIA patients 
stimulation with IL-6 resulted in a clear induction of p-STAT3, whereas in SF monocytes 
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STAT3 activation did not exceed baseline levels. These preliminary data demonstrate a 
definite tendency towards reduced IL-6 responsiveness in SF compared to PB monocytes. 
 
Figure 3-26: Basal STAT3 phosphorylation and IL-6 responsiveness in PB and SF monocytes. 
A) Flow cytometry of p-STAT3 from PB and SF (2.2.2.4.3). Cells were fixed with 1% (w/v) PFA, 
erythrocytes were lysed and cells were permeabilized by the addition of ice-cold methanol prior to 
staining with antibodies against p-STAT3 and CD14. The gate was set on CD14
+
 cells. Symbols 
indicate p-STAT3 MFI of individual donors (n = 14). Horizontal lines represent mean values plus SEM; 
** p<0.01 (two-tailed, paired t-test). B) FACS analysis of p-STAT3 (2.2.2.4.2). Erythrocytes were lysed 
prior to incubation with IL-6 (20 ng/ml) for 15 min. Cells were fixed, permeabilized and stained with 
antibodies against p-STAT3 and CD14. CD14
-
 cells were excluded by gating and MFI values of 
p-STAT3 measured in untreated cells were set to 1. Horizontal lines show mean plus SEM (n = 4). 
In vitro stimulations with SF led to downregulation of gp130 on PB monocytes and could thus 
mimic the situation in the inflamed joint. Since SF monocytes displayed increased levels of 
activated STAT3 compared to PB monocytes, we investigated the potential of SF to induce 
STAT3 phosphorylation. PBMCs were incubated with SF or HS as control and STAT3 
phosphorylation was determined. Samples were prepared in duplicate, one half being 
incubated with IL-6 20 min after the addition of SF or HS. As demonstrated by figure 3-27 A, 
the stimulation with SF resulted in a significant induction of p-STAT3. HS had no effect on 
STAT3 phosphorylation, independent of the presence or absence of IL-6. The additional 
incubation with IL-6 after stimulation with SF barely triggered any further STAT3 
phosphorylation at all. Despite a slight induction of p-STAT3 after SF and IL-6, STAT3 
activation still differs significantly from activation with IL-6 alone. 
Since the anti-inflammatory cytokine IL-10 is known to be an inducer of p-STAT3 (Lang et al., 
2002), and it has furthermore been reported that IL-10 is present in the SF of RA patients (de 
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Jager et al., 2007) the potential of IL-10 to activate STAT3 was compared to that of IL-6. 
According to figure 3-27 B, stimulation of PBMCs with IL-10 resulted in an amount of 
phosphorylated STAT3 comparable to that induced by IL-6. 
 
 
Figure 3-27: Influence of SF and IL-10 on STAT3 phosphorylation.  
FACS analysis of p-STAT3 (2.2.2.4.2). Cells were stained with antibodies against p-STAT3 and CD14 
and MFI of p-STAT3 was determined within the CD14
+
 population. A) HS or SF (10%, v/v) was added 
to PBMCs 20 min prior to the stimulation with IL-6 (20 ng/ml) for 10 min. MFI values of p-STAT3 
measured for IL-6-treated cells were set to 1. Bars show mean plus SEM (n = 24); *** p<0.001 (two-
tailed, paired t-test). B) PBMCs were stimulated with IL-6 or IL-10 (both 20 ng/ml) for 10 or 20 min. 
Bars represent mean plus SEM (n = 4). 
In line with the reduced expression of the IL-6 receptor complex on SF monocytes, 
preliminary data showed a diminished capacity of these cells to activate STAT3 in response 
to IL-6 compared to PB monocytes. Levels of basal STAT3 phosphorylation, however, were 
increased in SF monocytes from JIA patients, compared to PB monocytes. This increase of 
STAT3 activation could again be well mimicked by adding SF to PB monocytes. Further 
induction of p-STAT3 after incubation with SF by IL-6 stimulation was only marginal. IL-10 
was able to induce STAT3 phosphorylation in PB monocytes to a level comparable to that 
induced by IL-6.  
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4 DISCUSSION 
IL-6 signaling plays an important role in different immune reactions. Several regulatory 
mechanisms exist to avoid an overshooting response of cells to IL-6. It is becoming 
increasingly clear that apart from classical regulation, certain cytokines exert inhibitory 
effects on IL-6 signaling (Garbers et al., 2012).  
The aim of the first part of this study was to investigate whether crosstalk regulation of IL-6 
signaling takes place in human monocytes. IL-1β was chosen as pro-inflammatory stimulus 
and stimulation with this cytokine restricted IL-6 signaling (3.1.2) by downregulation of gp130 
surface expression (3.1.1). As hypothesized from previous studies in other cell types, these 
effects depended on the MAPK p38 (3.1.3). In hepatocytes the phosphorylation of serine 782 
within the cytoplasmic tail of gp130 was responsible for internalization of the receptor in 
response to pro-inflammatory stimuli (Radtke et al., 2010). As expected, the stimulation of 
monocytes with IL-1β resulted in increased phosphorylation of this particular residue (3.1.4). 
The analogous serine and the upstream serine residue in the mouse were used to generate 
transgenic mice in the second part of this study. Two different constructs were cloned 
successfully and two transgenic strains were established (3.2) – one overexpressing 
gp130-wt and one overexpressing a mutated version of gp130 with non-phosphorylatable 
serine 778/780. Despite breeding problems, mice were partially characterized. Gp130 
expression was differentially regulated by IL-1β on splenocyte subsets in the two strains 
(3.2.2). Our hypothesis that the serine mutation in gp130 would alter cell surface expression 
and downstream signaling was further supported by different migratory behavior of myeloid 
cells after zymosan-induced peritonitis in gp130-mut compared to gp130-wt mice (3.2.3). 
In the third part of the study regulation of gp130 signaling was investigated in chronic 
inflammatory disorders. Two different diseases were taken into consideration: IBD and JIA. 
Both conditions are accompanied by increased serum levels of IL-6, IL-1β and TNF-α. The 
hypothesis that gp130 surface expression and downstream signaling might be altered was 
confirmed for PB monocytes in IBD patients compared to healthy controls (3.3.1.1). The 
changes observed in PB monocytes of IBD patients were successfully transferred to a 
murine model of chronic colitis (3.3.1.2). Differences in gp130 expression were furthermore 
identified in SF monocytes of JIA patients compared to PB monocytes of the same patient 
(3.3.2.1). Stimulation of PBMCs with SF from JIA patients resulted in a MAPK 
p38-dependent downregulation of gp130 expression comparable to the situation in the 
inflamed joint (3.3.2.1). 
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4.1 Crosstalk regulation of IL-6 signaling in human monocytes 
4.1.1 Internalization of gp130 
Data from the first part of this study indicate that IL-1β induces a downregulation of gp130 
surface expression on monocytes. Figure 3-2 A and B show that in the presence of IL-1β 
enhanced internalization of gp130 occurs. Even in the absence of IL-1β internalization was 
apparent to a certain degree. Constitutive turnover of gp130 was observed earlier in other 
cell types (Thiel et al., 1998b) and it turned out to be true for primary human monocytes as 
well. The effect of IL-1β on gp130 surface expression was illustrated more clearly by confocal 
microscopy than by flow cytometry (figure 3-2). One main difference in sample preparation 
between the two methods was the order of stimulation and staining. For flow cytometry cells 
were stimulated with IL-1β, washed and subsequently incubated with antibodies on ice to 
prevent further internalization. After another washing step cells were directly analyzed by 
flow cytometry. For live-cell imaging cells were incubated with antibodies on ice, washed to 
remove non-bound antibodies and subsequently analyzed in the presence or absence of 
IL-1β at 37°C. Thus, during the period of stimulation no antibodies were bound to gp130 in 
the preparation for FACS analysis in contrast to sample preparation for microscopy. It may 
therefore be supposed that the antibody bound to the gp130 epitope exerted a stimulatory 
effect on gp130 internalization. Although it is known that after ligand binding the IL-6 receptor 
complex is internalized, a process depending on the di-leucine motif in the cytoplasmic tail of 
gp130, it has also been shown that JAK activation is not necessary for this process (Dittrich 
et al., 1994; Thiel et al., 1998a). Furthermore, the antibody used here was found to act 
antagonistically on gp130 activation (Wijdenes et al., 1995). Another potentially important 
difference between sample preparations for flow cytometry and microscopy concerns the 
purity of monocytes. For the FACS analysis shown in figure 3-2 C, PBMCs were stimulated 
and CD14- cells were excluded by gating. However, for microscopy, monocytes were 
enriched by allowing them to settle down, followed by stringent washing. Consequently, the 
numbers of lymphocytes were probably reduced in microscopy assays compared to flow 
cytometry. To what extent this might have influenced internalization of gp130 is not known. 
To exclude potential effects of lymphocytes on monocytic gp130 surface expression, pure 
monocyte populations should be used. Enrichment of monocytes by adherence was not only 
well suited but also necessary for microscopy because adherence of cells is a prerequisite 
for focusing on the correct layer. For flow cytometric analyses, however, this method would 
be less suitable, since cells would need to be removed from plastic dishes prior to 
preparation for FACS. Another aspect of the enrichment of monocytes by adherence used for 
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microscopy is the fact that adherence to plastic partially activates the cells (de Almeida et al., 
2000). It cannot be excluded that this cell activation had an influence on internalization. 
One commonly used method of monitoring internalization of cell surface proteins by flow 
cytometry is to label the respective protein with an antibody and to incubate the cells with the 
stimulus expected to induce internalization. Subsequently, antibodies bound to the cell 
surface are removed by an acid wash and cells are subjected to flow cytometry to visualize 
only internalized antibodies. The problem with these internalization assays is that surface-
bound antibodies are not always removed efficiently (Helchowski et al., 2009). Furthermore, 
although such assays may be suitable for relatively robust cell lines, primary monocytes are 
quite sensitive and no longer usable for flow cytometry after an acid wash (own 
observations). An alternative, as yet untested, approach to illustrating internalization of 
gp130 more clearly would be the fractionation of cell membranes from cytoplasm after IL-1β 
stimulation. Gp130 could be visualized in a western blot in both compartments and compared 
to untreated cells. However, this is a quite laborious and time-consuming method and it 
seems questionable whether the sensitivity would be sufficient to detect small changes in 
expression.  
4.1.2 Crosstalk inhibition of STAT3 phosphorylation  
The reduced gp130 surface expression in response to IL-1β was expected to impair 
downstream signaling. STAT3 phosphorylation was determined as readout for IL-6 signaling. 
STAT3 is known to be phosphorylated after a few min in response to IL-6 with a peak around 
15-30 min (Kortylewski et al., 1999). Indeed, after 10 min of IL-6 stimulation about 9-fold 
levels of p-STAT3 compared to untreated PBMCs were detected in a western blot (figure 
3-3 A). After pre-stimulation with IL-1β levels of p-STAT3 increased only about 3-fold 
compared to untreated cells. These results confirmed our expectations and were reproduced 
by a flow cytometric approach (figure 3-3 B). Since these experiments were performed with 
PBMCs, rather than with isolated monocytes, neither method excludes co-stimulatory effects 
of lymphocytes. Whereas in the FACS analysis a gate was set on CD14+ cells to examine 
only the monocyte population, the western blot includes lymphocytes. Monocytes account for 
approximately 10% of PBMCs. Thus, it might be concluded that the effects observed in the 
western blot are primarily due to lymphocytes and that in this cell population IL-1β restricts 
IL-6 signaling as well. However, expression of IL-6R on PBMCs is largely restricted to 
monocytes and some subsets of T and B cells (Jones et al., 2001) suggesting that 
stimulation with IL-6 alone would activate STAT3 predominantly in these cells, among which 
monocytes represent the strongest fraction.  
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To exclude co-stimulatory effects of lymphocytes on gp130 surface expression or IL-6 
signaling in monocytes, Percoll gradients were used to isolate monocytes from PBMCs. 
Restriction of IL-6 signaling by pre-stimulation with IL-1β in isolated monocytes was 
comparable to PBMCs gated on CD14+ cells (figure 3-3 B and C) showing that lymphocytes 
are dispensable for crosstalk regulation in monocytes. 
One of the most potent mechanisms for shutting off STAT3 activation is the inactivation of 
JAKs by the feedback inhibitor SOCS3. Expression of SOCS3 rises rapidly after IL-6 
stimulation and a stabilization of SOCS3 mRNA by IL-1β has been described for hepatocytes 
(Heinrich et al., 2003; Yang et al., 2004). The question whether reduction of IL-6-induced 
STAT3 phosphorylation by IL-1β was dependent on SOCS proteins was therefore examined. 
By pre-incubation of the cells with actinomycin D, which intercalates with DNA and thus 
inhibits the synthesis of mRNA, transcription was blocked. The inhibitory effect of IL-1β on 
IL-6-induced STAT3 activation was unchanged in the absence of protein synthesis (figure 
3-4 A) showing that it was independent of SOCS3. Although the use of actinomycin D as an 
inhibitor of protein synthesis is well-established, it cannot be inferred from this experiment 
that transcription was successfully blocked. To confirm the efficacy of actinomycin D, cells 
should be stimulated with IL-6 after pre-treatment with the inhibitor or the vehicle DMSO. 
Subsequently, expression of SOCS3 should be determined either by quantitative RT-PCR or 
by western blotting or FACS analysis at the protein level. Figure 3-4 B shows quantitative 
RT-PCR data, from which it was concluded that SOCS3 expression was induced only 
marginally after 10 min of IL-6 stimulation and that this induction was not significantly 
increased by co-stimulation with IL-1β. Still there was a slight induction of SOCS3 expression 
after IL-6 and after IL-1β stimulation compared to untreated cells. These effects seemed to 
be additive, since the combined stimulation with both cytokines further increased the 
induction minimally. These results demonstrate that in monocytes expression of SOCS3 
induced by IL-6 seems to be very rapid and that IL-1β has the potential to induce SOCS3 
expression. It has been shown before that stimulation of macrophages with IL-1β results in 
the induction of SOCS3 (Ahmed and Ivashkiv, 2000). Since IL-1β alone was able to slightly 
induce SOCS3 expression, this effect probably differs from the mRNA stabilization observed 
by Yang et al. However, it cannot be completely excluded that minimal basal levels of 
SOCS3 mRNA are present in the cell and that IL-1β inhibited their degradation. Still, we 
concluded from these results that the inhibitory effect of IL-1β on IL-6-induced STAT3 
phosphorylation was not primarily due to the action of SOCS3.  
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4.1.3 Involvement of p38 
Crosstalk inhibition of IL-6 signaling in macrophages and hepatocytes has been shown to be 
dependent on p38 (Ahmed et al., 2002; Radtke et al., 2010). For this reason we 
hypothesized that p38 might be an important element in the signaling cascade induced by 
IL-1β leading to reduced gp130 surface expression on monocytes. Figure 3-5 shows that 
IL-1β induces phosphorylation of p38 in monocytes. This is consistent with earlier studies, 
which identified IL-1β and TNF-α as potent inducers of p38 (Raingeaud et al., 1995). The 
inhibition of p38 restored gp130 surface expression after stimulation with IL-1β (figure 3-6 A), 
thus demonstrating the involvement of the MAPK in downregulation of gp130. This was 
reflected in the level of downstream signaling, i.e. treatment with SB202190 reconstituted 
IL-6-induced STAT3 phosphorylation after IL-1β stimulation (figure 3-6 B). The incubation of 
cells with the inhibitor alone resulted in a minimal increase in gp130 surface expression, 
which again was reflected in the level of downstream signaling. IL-6-induced STAT3 
phosphorylation was slightly stronger after pre-incubation with SB202190 compared to cells 
pre-incubated with DMSO (figure 3-6 B). These findings indicate that a certain basal 
activation of p38 might occur in the absence of IL-1β stimulation. Since p38 is a stress-
activated MAPK, it may be induced by various stimuli. A similar picture was observed in 
hepatocytes (Radtke et al., 2010). Reduced STAT3 phosphorylation after pre-stimulation with 
IL-1β was reconstituted to levels observed without SB202190 treatment, however, a 
complete restoration to levels observed after p38 inhibition was not achieved (figure 3-6 B). 
One explanation could be the slight induction of SOCS3 by IL-1β (figure 3-4 B), which may 
have contributed to the inhibitory effect of IL-1β on IL-6-induced STAT3 activation.  
The kinase MK2, which is activated by p38, was responsible for the phosphorylation of serine 
782 in the cytoplasmic domain of gp130 in hepatocytes (Radtke et al., 2010). Serine 782 is 
part of a consensus sequence for MK2 and is located close to the di-leucine internalization 
motif of gp130. Phosphorylation of this residue was slightly increased in monocytes by 
stimulation with IL-1β (figure 3-7). However, the phosphorylation in untreated cells was also 
quite pronounced and differed from that found in hepatocytes, which might indicate 
unspecific binding of the used antibody. A control with an irrelevant antibody of matching 
isotype could be included to rule out the possibility of an unspecific cross reaction with that 
particular isotype. On the other hand, to our knowledge this is the first study examining 
phosphorylation of serine 782 in primary monocytes and it may be that phosphorylation 
levels differ from those observed in hepatocytes. Whether this basal phosphorylation leads to 
internalization and high turnover is inherent to monocytes is not clear. Stress due to isolation 
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procedures might have led to increased phosphorylation via p38 and as a consequence 
further phosphorylation by the additional stimulus IL-1β was weak. To confirm that the 
phosphorylation of serine 782 occurs via p38 and MK2, inhibitors of the kinases should be 
included in the analysis. In practice, the visualization of endogenous gp130 in primary 
monocytes is challenging. High numbers of cells are required to provide sufficient protein 
amounts for immunoprecipitation. Furthermore, the isolation of monocytes by Percoll 
gradients resulted in variable yield and purities, probably depending on quality of buffy coats. 
Isolation of monocytes by magnetic beads would represent an alternative approach, 
however, negative selection is very expensive due to the rather small fraction of PBMCs 
accounting for monocytes and positive selection has been shown to activate monocytes 
comparable to purification by adherence (Seager Danciger et al., 2004).   
4.1.4 Physiological relevance 
The crosstalk regulation of IL-6 signaling presented by IL-1β is most likely to be of particular 
relevance in physiological situations where cells need to react to a complex network of 
stimuli represented by many different cytokines. Pro- and anti-inflammatory properties have 
been described for IL-6. It seems that the overall role of the cytokine depends critically on the 
cell type affected, but also on modulatory actions on signal transduction. It is known that 
differential signaling thresholds are required for the induction of target genes (Ernst and 
Jenkins, 2004). This is exemplified by the transcription factor STAT3, which is activated not 
only by IL-6-type cytokines, but also by other cytokines including IL-10. IL-10 is a typical anti-
inflammatory cytokine and often opposes the actions of IL-6 (Fiorentino et al., 1991). These 
converse functions of p-STAT3 are due to differential durations of signaling, which are 
controlled by SOCS3. Essentially, SOCS3 exerts feedback inhibition on gp130-mediated 
signaling, whereas IL-10 signaling remains unaffected. In macrophages lacking the Socs3 
gene the actions of IL-6 resemble those of IL-10 (Yasukawa et al., 2003). Interestingly, mice 
carrying a mutation in the cytoplasmic domain of gp130, abolishing binding of SOCS3 and 
SHP2, show hyperactivation of STAT3, which is associated with defects in hematopoiesis 
(Jenkins et al., 2005). Subtle differences in expression levels of p-STAT3 due to the 
generation of these mice with murine or a partial human cDNA result in phenotypic variations 
(Ernst and Jenkins, 2004). This clearly indicates the significance of STAT3 signaling strength 
for biological outcome. Hence, the crosstalk mechanism presented herein could serve to 
modulate the threshold of STAT3 signaling and contribute critically to the biologic response 
of the cell. IL-1β and IL-6 are often co-expressed at sites of inflammation. By reducing 
IL-6-induced STAT3 activation, IL-1β could counterbalance potential additive 
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pro-inflammatory effects of both cytokines and thus prevent an overshooting inflammatory 
reaction. On the other hand, since IL-6 displays anti-inflammatory effects, especially on 
myeloid cells (Tilg et al., 1994), IL-1β might intensify inflammation by downregulation of 
gp130 expression. Taking into account the fact that prolonged STAT3 activation in 
macrophages elicits rather anti-inflammatory, IL-10-like responses, it seems conceivable that 
IL-1β, by supporting the termination of IL-6-induced STAT3 activation, could strengthen 
pro-inflammatory actions of IL-6. The use of STAT3 as transcription factor by more than one 
cytokine makes it difficult to distinguish the contribution of each cytokine in vivo. 
Gp130-mediated STAT3 phosphorylation can be triggered not only by IL-6 but also by 8 
other cytokines belonging to the IL-6 family (Heinrich et al., 1998). Signaling of these 
cytokines could likewise be affected by IL-1β-mediated downregulation of gp130 expression. 
The modulation of p-STAT3 signaling strength by IL-1β is illustrated in figure 4-1. 
 
Figure 4-1: Modulation of p-STAT3 signaling strength by IL-1β.  
Depending on the signaling threshold of p-STAT3, pro- or anti-inflammatory genes can be induced. By 
exerting an inhibitory effect on IL-6 signaling, IL-1β can modulate the signaling strength and thus the 
biological response of a cell. 
4.2 Mouse model of crosstalk regulation 
To study crosstalk regulation in vivo, transgenic mice were generated. We decided to 
overexpress gp130 in the complete hematopoietic compartment under the control of the vav 
promoter. To create a version of gp130 that would prevent potential crosstalk mechanisms 
mediated by serine phosphorylation and internalization, two serine residues were mutated to 
alanines. In addition to serine 780, which is analogous to human serine 782, serine 778, 
analogous to human serine 780, was mutated (figure 3-9). Serine 782 is potentially involved 
in crosstalk regulation in human monocytes (3.1.4) and serves as a stress sensor limiting 
gp130-mediated signaling by internalization (Gibson et al., 2000; Radtke et al., 2010). An 
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earlier study using human cell lines demonstrated an influence of serine 780 on receptor 
internalization (Dittrich et al., 1996). Later on it was proposed that the residue crucial for 
internalization is serine 782, but that serine 780 is required for its phosphorylation (Gibson et 
al., 2000). The cytoplasmic tail of gp130 is highly conserved between humans and mice 
(figure 3-9). So far, to our knowledge the only study that has been conducted in murine cells 
concerning the role of serine phosphorylation in receptor internalization is that of Radtke et 
al. In murine embryonal fibroblasts (MEFs), stimulation with IL-1β results in serine 
phosphorylation and downregulation of gp130, both of which depends on p38 and MK2 
(Radtke et al., 2010). Furthermore, studies with primary murine macrophages support the 
finding that crosstalk regulation of gp130-mediated signaling by pro-inflammatory stimuli 
occurs in mouse cells (Kiu et al., 2007). We therefore generated gp130-mut mice, 
overexpressing a version of gp130, which is non-phosphorylatable at the two mentioned 
serine residues. A second mouse strain was generated, which overexpresses gp130-wt as 
reference for gp130-mut mice. After successful cloning of the different constructs (figure 3-8), 
the respective mouse strains were generated by pronuclear injection.  
To detect the inserted gene, a PCR reaction was established and the mice identified as 
carrying the transgene were characterized. Quantitative RT-PCR of splenocytes showed 
enhanced gp130 expression in both mouse strains compared to mice without transgene 
(figure 3-10). Expression in gp130-wt was slightly stronger than in gp130-mut splenocytes. 
The gp130 mRNA levels were not expected to differ between gp130-wt and gp130-mut mice, 
since the SS/AA mutation was assumed to influence cell surface expression but not basal 
expression levels. Through pronuclear injection transgenes are randomly integrated into the 
genome, rather than being targeted to a specific site. Furthermore, the number of copies 
cannot be influenced (Beard et al., 2006). Thus, gp130-wt mice might have integrated more 
copies of the transgene compared to gp130-mut.  
4.2.1 Surface expression of gp130 
To avoid interference with normal physiology, the inserted gp130 was not marked by a tag. 
Thus, discrimination between transgene and endogenous gp130 on the protein level was not 
possible.  
In terms of gp130 surface expression differences between the two strains were detected on 
leukocytes from PB, which were most pronounced in B cells (figure 3-11). On splenocytes 
gp130 surface expression levels were comparable between gp130-wt and gp130-mut mice 
(figure 3-12) and thus not in line with data from quantitative RT-PCR suggesting lower gp130 
expression in gp130-mut compared to gp130-wt mice. However, mRNA expression will not 
  DISCUSSION 
73 
 
necessarily be reflected in surface expression, since post-translational modifications or 
altered turnover can lead to differences. Assuming that gp130-mut splenocytes express 
lower levels of gp130 protein than gp130-wt splenocytes, but that both strains show similar 
levels of surface expression, this could indicate an increased stability of the gp130-mut 
protein on the cell surface. To clarify whether total gp130 protein levels differ between 
gp130-wt and gp130-mut splenocytes, gp130 protein amounts could be determined by 
western blotting or intracellular FACS analysis.  
The mutation of serine 778 and 780 was hypothesized to increase the stability of gp130 
surface expression and it was assumed that this increased stability would become apparent 
after stimulation of the cells with pro-inflammatory cytokines. The incubation of splenocytes 
with IL-1β resulted in a slight downregulation of gp130 surface expression on gp130-wt 
B cells and myeloid cells (figure 3-14 C-D). Although this change of surface expression was 
very small, it was still significantly different from expression on the respective cell population 
from gp130-mut mice after IL-1β stimulation. In the latter, no changes of gp130 surface 
expression by IL-1β were observed on B cells and even a slight increase could be detected 
on CD11b+ cells (figure 3-14 C-D). These results provide first hints that the findings from 
human monocytes may be transferable to the murine system and that mutation of 
serine 778/780 may affect internalization in response to IL-1β.   
4.2.2 Activation of STAT3 
Although basal gp130 surface expression on gp130-wt T cells did not differ from gp130-mut 
T cells, differential STAT3 activation was observed. In response to IL-6, significantly more 
p-STAT3 could be detected in gp130-mut compared to gp130-wt T cells (figure 3-13 B). 
Since this enhanced response to IL-6 could not be due to higher levels of available gp130 
molecules at the cell surface, remaining possibilities include an increased expression of 
IL-6R or an altered signal transduction. There is no obvious reason why the expression of 
IL-6R should have been enhanced on gp130-mut T cells, however, it was not tested and 
therefore cannot be completely excluded. Serine residues 778/780 are located between the 
two STAT3 binding sites tyrosine 765 and tyrosine 812. Other studies, which have worked 
with human gp130 mutated at one or two of the equivalent serine residues, have not 
investigated downstream signaling compared to non-mutated gp130 (Dittrich et al., 1996; 
Radtke et al., 2010). Still it seems unlikely that the exchange of serine to alanine had an 
effect on STAT3 binding, and this is supported by the fact that no changes in IL-6 
responsiveness were observed for other splenocytes subsets (figure 3-13 C-D). The factors 
accounting for the increased IL-6-induced STAT3 activation in the T cell fraction of 
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gp130-mut splenocytes are not clear. 
Consistent with the finding that IL-1β had no influence on gp130 surface expression of 
gp130-wt or gp130-mut T cells, stimulation with IL-1β did not change IL-6-induced STAT3 
phosphorylation in the T cell subset of either of the mouse strains (figure 3-15 B). In contrast, 
in B cells and myeloid cells slight changes of IL-6-induced STAT3 phosphorylation by IL-1β 
were observed. In myeloid cells this tendency was in line with gp130 surface expression: 
IL-1β downregulated gp130 surface expression (figure 3-14 D) and IL-6-induced STAT3 
phosphorylation in gp130-wt CD11b+ cells, but not, or to a lesser extent, in gp130-mut cells 
(figure 3-15 D). Thus, it seems possible that results from human monocytes are transferable 
to some extent to CD11b+ splenocytes. In contrast to myeloid cells, in B cells the changes of 
gp130 surface expression after IL-1β stimulation were not reflected in the level of STAT3 
phosphorylation (figure 3-14 C and figure 3-15 C). Since differences detected for IL-6-
induced STAT3 activation after incubation with IL-1β were not significant in either of the 
investigated cell types, it cannot be excluded that they represent normal levels of variation. 
Because of breeding problems in both strains at different time points, the number of animals 
included in our analyses is quite low. It is possible that the observed tendencies would 
become more apparent in a larger population sample. Furthermore, other pro-inflammatory 
stimuli such as TNF-α or LPS might have stronger effects in the murine system than IL-1β. In 
a study with primary macrophages, differentiated from bone marrow, inhibitory effects of 
TNF-α and LPS on IL-6-induced STAT3 phosphorylation have been described (Kiu et al., 
2007). It is also conceivable that another cell type is a more suitable system in which to 
explore crosstalk mechanisms. Since the inserted gp130 was not distinguishable from 
endogenous gp130, it remains unclear to what extent endogenous gp130 might have 
weakened the observed differences between the two mouse strains.  
4.2.3 Migration of leukocytes  
Data from zymosan-induced peritonitis, a model for leukocyte migration into the peritoneal 
cavity, showed increased leukocyte migration in gp130-mut mice in comparison to gp130-wt 
animals (figure 3-16). IL-6-mediated signals influence migration of leukocytes by different 
mechanisms. In epithelial cells in particular, IL-6 trans-signaling has been described as an 
important mechanism to induce chemokine secretion resulting in leukocyte recruitment 
(Hurst et al., 2001). Direct effects of IL-6 on the migratory potential of human T cells and 
monocytes have been shown as well (Clahsen and Schaper, 2008; Weissenbach et al., 
2004) and similar findings have been obtained in murine macrophages (Koon et al., 2009). 
Mice with gp130-deficient macrophages and neutrophils show decreased migration in a 
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model of peritonitis compared to their wildtype littermates (Sander et al., 2008), which further 
supports the notion of IL-6 acting directly as a migration factor on myeloid cells. It is thus 
conceivable that increased stability of gp130 surface expression in gp130-mut mice leads to 
an enhanced migratory potential of myeloid cells.  
4.3 Regulation of gp130 signaling in chronic disease 
4.3.1 IBD 
Pediatric patients with IBD displayed increased levels of gp130 surface expression on 
monocytes compared to healthy controls (figure 3-17 A-B). Expression levels of IL-6R, 
however, were not changed (figure 3-17 C). The upregulation of gp130 alone seemed to be 
sufficient to lead to an increased STAT3 activation (figure 3-18). This might be due to a 
milieu where high levels of IL-6 and sIL-6R are present (Mudter and Neurath, 2007). 
Trans-signaling could have contributed to enhanced STAT3 phosphorylation in monocytes 
with increased expression levels of gp130. This is consistent with studies on cell types 
expressing both, gp130 and IL-6R where gp130 expression was reported to be generally 
higher than that of IL-6R (Jones et al., 2011). However, it might also be possible that the 
expression of IL-6R on monocytes was high enough to bind many IL-6 molecules and to 
build an increased number of complexes with gp130. Both scenarios lead to the conclusion 
that the expression of gp130 rather than the expression of IL-6R for downstream signaling is 
likely to be the limiting factor. This highlights the importance of a strictly regulated gp130 cell 
surface expression. However, it cannot be excluded from the experiments performed here 
that other factors were responsible for the increased amount of p-STAT3 in monocytes of 
IBD patients. The anti-inflammatory cytokine IL-10 is known to be a potent inducer of STAT3 
activation. However, the high serum levels of IL-6 in IBD patients make it tempting to 
hypothesize that increased STAT3 activation was induced by IL-6.  
Considering the fact that the IL-6 receptor complex is internalized after ligand binding and 
that gp130 expression underlies potential crosstalk regulation by other pro-inflammatory 
cytokines such as IL-1β or TNF-α, which are abundantly present in serum of IBD patients, 
the observed increase in gp130 surface expression was unexpected. In this context it is 
interesting that exon 17 of gp130 was examined for mutations or polymorphisms in patients 
with IBD. One could speculate that mutations of the internalization motif might explain the 
observed effects and play a role in IBD pathophysiology. However, the study of 
Auernhammer et al. demonstrated that none of the tested patients carried a mutation or 
polymorphism in exon 17 of gp130 (Auernhammer et al., 2005), which accounts for most of 
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the intracellular domain and also includes the internalization motif and serine 782. It is 
unclear which factors resulted in upregulation of gp130 surface expression and STAT3 
activation.  
Intriguingly, it has been reported from in vitro studies that IL-6 enhances gp130 mRNA in 
human monocytes and other cell types (Schoester et al., 1994; Schooltink et al., 1992). 
Furthermore, O’Brien et al. have proposed a STAT-binding element in the gp130 promoter 
(O'Brien and Manolagas, 1997). Whereas these studies have investigated mRNA 
expression, which is not necessarily an indicator of cell surface expression, it has also been 
reported that in mast cells gp130 surface expression is up-regulated by IL-10-induced STAT3 
activation (Traum et al., 2012). These lines of evidence suggest that the observed increase 
in gp130 surface expression on monocytes from IBD patients might be induced by elevated 
p-STAT3 levels.  
Interestingly, it was shown earlier that mRNA expression levels of the IL-6 receptor complex 
are increased in circulating lymphocytes of patients with IBD (Holub et al., 1998). 
Furthermore, Carey et al. reported that STAT3 phosphorylation is elevated in circulating 
neutrophils of pediatric IBD patients and suggested that this was IL-6-induced. The study 
additionally revealed a correlation between the frequency of neutrophils with activated 
STAT3 and mucosal inflammation (Carey et al., 2008).  
What consequences might arise from increased gp130 surface expression and STAT3 
phosphorylation in monocytes of IBD patients? The overall role of p-STAT3 in IBD is 
ambiguous and clearly depends on the cell type. The anti-inflammatory effects of p-STAT3 
are often emphasized in macrophages. However, as mentioned earlier, STAT3 is also 
activated in response to IL-10 and the biological outcome seems to depend strictly on 
signaling strength and duration (4.1.4). The deficiency of gp130 in macrophages and 
neutrophils leads to reduction of DSS colitis in mice (Sander et al., 2008), obviously arguing 
against an anti-inflammatory role of gp130-mediated p-STAT3 in these cell types. The 
biologic effects of IL-6 on monocytes are even less clear. Since IL-6 acts as a direct 
migration factor on human monocytes, it is conceivable that the increased gp130-mediated 
signaling in monocytes of IBD patients leads to an upregulation of adhesion molecules. At 
the site of inflammation, in the lamina propria, IL-6 might act as chemotactic factor and 
attract monocytes to infiltrate the tissue. 
The administration of infliximab, a monoclonal anti-TNF-α antibody, to children with IBD 
resulted in downregulation of gp130 (figure 3-19 A) and consistently also of p-STAT3 
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expression in monocytes (figure 3-19 B). Thus, the neutralization of TNF-α had an impact on 
gp130 surface expression and downstream signaling. The mechanism behind this 
observation is unclear, but it cannot be excluded that it might influence clinical efficacy. 
Interestingly, anti-TNF agents have been shown to bind to Fc receptors and thereby 
modulate their own inhibitory efficacy, as well as inducing Fc-mediated signaling. A recent 
study has reported that the capacity of infliximab to inhibit TNF-mediated responses in 
PBMCs from IBD patients is rather low (Wojtal et al., 2012). Furthermore, infliximab was 
shown to induce apoptosis in monocytes by a mechanism involving membrane-bound TNF-α 
(Lugering et al., 2001). Therefore, it is possible that the observed effects on gp130 surface 
expression and STAT3 phosphorylation were due to signaling via membrane-bound TNF-α 
or via Fc receptors instead of neutralization of TNF-α. 
Since the small amount of blood obtained from IBD patients restricts the spectrum of 
possible analyses, chronic colitis was induced in mice. The aim was to determine possible 
parallels between the observations made in human IBD monocytes and the murine system. 
Indeed, in analogy to human IBD patients, mice suffering from DSS-induced colitis displayed 
an increased expression of gp130 on CD11b+ cells at the end of the experiment compared to 
untreated mice (figure 3-21 A). This was reflected in the level of downstream signaling, i.e. 
DSS-treated mice showed increased STAT3 phosphorylation in CD11b+ cells at day 37 
compared to day 1 and to untreated mice (figure 3-21 B).  
Many studies of murine colitis models have reported enhanced STAT3 phosphorylation in the 
colon (Lee et al., 2012; Suzuki et al., 2001). However, to our knowledge STAT3 activation in 
circulating leukocytes has not yet been investigated. As speculated concerning the human 
system, it could be that increased levels of gp130 surface expression and STAT3 
phosphorylation contribute to an upregulation of adhesion molecules and act on the 
migration of myeloid cells.  
Interestingly, the situation was reversed in mesenteric lymph nodes. CD11b+ cells in this 
immune compartment of DSS-treated mice displayed lower levels of gp130 surface 
expression and STAT3 phosphorylation compared to control mice (figure 3-22). The 
mechanisms regulating increased gp130 surface expression and STAT3 phosphorylation in 
circulating myeloid cells and decreased gp130 surface expression and STAT3 
phosphorylation in myeloid cells in the mesenteric lymph nodes are unclear. It is conceivable 
that cell-cell contacts or the close proximity to cells secreting soluble factors in the lymph 
nodes had a regulatory impact on gp130 surface expression.  
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4.3.2 JIA 
Reduced surface expression of the IL-6 receptor complex was found on SF monocytes from 
patients with JIA compared to PB monocytes (figure 3-23). We hypothesized that soluble 
factors accounting for the highly inflammatory environment in the joint were responsible for 
the observed receptor downregulation by internalization. Indeed, gp130 expression was 
reconstituted after isolation of the cells from SF and after up to 1 hour of rest. In contrast, 
IL-6R levels remained constant (figure 3-24 A). The situation in the inflamed joint was 
mimicked by incubating PBMCs from healthy donors with SF. A rapid downregulation of both 
components of the IL-6 receptor complex was detected after 20 min of stimulation (figure 
3-24 B-C). The loss of gp130 cell surface expression was slightly stronger compared to 
IL-6R.  
Why gp130 re-appeared on the cell surface after 30 min of rest and IL-6R surface expression 
remained at very low levels, was not clarified. Normally, after endocytosis receptors are 
either sorted into recycling endosomes to be transported back to the plasma membrane or 
they are degraded by the lysosomal pathway (Sorkin, 2000). Internalization of the IL-6 
receptor complex is ligand-induced. Re-appearance of IL-6 binding sites after ligand-induced 
internalization in hepatocytes requires >8 h and is sensitive to cyclohexamide, which 
indicates a dependence on new protein synthesis and thus lysosomal degradation 
(Zohlnhofer et al., 1992). However, considering that the internalization of IL-6R alone is 
highly inefficient and its cytoplasmic domain is not essential for internalization of the receptor 
complex (Dittrich et al., 1994), the findings from SF monocytes indicate that downregulation 
of IL-6R depended on gp130. This further suggests that complexes of IL-6R and gp130 must 
have formed previously. Whether such complexes of gp130 and IL-6R become separated in 
the endosomes in order to be subsequently sorted differentially, is not known. An alternative 
explanation might be different kinetics for re-synthesis of the two receptor components. 
Association of gp130 and IL-6R normally occurs after binding of IL-6. Since high amounts of 
IL-6 are present in the SF, it may be hypothesized that the IL-6 receptor complex was 
internalized by a ligand-induced process and that this accounted for the observed reduced 
surface expression levels. Consistently, a recent study reported that gp130 and IL-6R 
expression on T cells was reduced by incubation with SF from RA patients and that this 
could be inhibited by an IL-6R blocking antibody (Hidalgo et al., 2011). However, levels were 
not completely restored after blockade of IL-6 signaling indicating an additional mechanism 
contributing to downregulation. This was supported by our own experiments in monocytes 
with the p38-specific inhibitor SB202190. Incubation of cells with SB202190 prior to the 
addition of SF partially restored surface expression of gp130 and IL-6R (figure 3-25). This 
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effect was again more pronounced for gp130 than for IL-6R. These results suggests that 
crosstalk mechanisms comparable to those observed in monocytes after IL-1β stimulation 
may be of importance in joint inflammation in patients with JIA. 
To investigate whether downstream signaling is affected by diminished surface expression 
levels of gp130 and IL-6R, STAT3 phosphorylation was analyzed in SF monocytes and 
compared to that in PB monocytes. Surprisingly, basal STAT3 phosphorylation was stronger 
in SF than in PB monocytes (figure 3-26 A). Since reduced availability of gp130 or even both 
receptor components on the cell surface strongly implicates decreased IL-6 responsiveness, 
STAT3 phosphorylation was determined after IL-6 stimulation. In accordance with low 
receptor availability, SF monocytes were largely unresponsive to IL-6 in contrast to PB 
monocytes (figure 3-26 B). Thus, it can be concluded that increased amounts of p-STAT3 in 
SF monocytes are likely to be induced by factors other than IL-6. One possible candidate is 
the anti-inflammatory cytokine IL-10, which was shown to induce STAT3 phosphorylation to 
an extent comparable to IL-6, though after a longer incubation time (figure 3-27 B). Similar to 
the downregulation of gp130 and IL-6R surface expression following incubation of PBMCs 
with SF, STAT3 phosphorylation was induced by stimulation with SF (figure 3-27 A). The 
addition of IL-6 after pre-incubation with SF resulted in only a slight further induction of 
p-STAT3 compared to stimulation with SF alone. One obvious reason for this could be the 
decreased amount of IL-6 receptor complexes on the cell surface. An alternative explanation, 
which most likely contributes to the diminished p-STAT3 induction by IL-6, is the induction of 
SOCS3. The feedback inhibitor SOCS3 is expressed, irrespective of the factor by which 
STAT3 is activated.  
As described in the section 4.1.4, the biological outcome of gp130-mediated signaling may 
be modulated by crosstalk inhibition. Whether the overall role of IL-6 is pro- or 
anti-inflammatory and how this is influenced by the decrease of gp130 and IL-6R surface 
expression can only be speculated. Actions of IL-6 on monocytes, which most likely 
contribute to a pro-inflammatory response in the inflamed joint, include the role of monocytes 
as osteoclast precursors. Normally, the action of bone-forming osteoblasts and bone-
resorbing osteoclasts is determined by a strictly regulated balance (Kwan Tat et al., 2004). 
However, in inflammatory situations this balance might be disturbed. The destruction of 
articular cartilage and bone is a hallmark in JIA and RA (Gravallese et al., 1998). It has been 
shown that IL-6 together with M-CSF is capable of inducing differentiation of CD14+ cells to 
osteoclasts (Kudo et al., 2003). The authors suggested that this mechanism may not be of 
relevance in normal bone physiology, but in pathological situations with increased amounts 
of cytokines. IL-6 was furthermore shown to up-regulate the expression of M-CSF receptors 
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on monocytes (Chomarat et al., 2000), which may amplify the induction of osteoclast 
formation by IL-6. Osteoclastogenesis moreover can be triggered by M-CSF in association 
with RANKL and IL-6 induces RANKL from T cells or synovial fibroblasts. The reduction of 
surface expression of the IL-6 receptor complex by soluble factors in the SF would, in this 
scenario, act as protective mechanism, averting an overwhelming pro-inflammatory reaction. 
Anti-inflammatory actions of IL-6 on monocytes include the induction of IL-1Ra. Increased 
amounts of IL-1Ra have been detected in SF of RA patients (Malyak et al., 1993). An 
overview of these mechanisms is given in figure 4-2.  
 
Figure 4-2: Possible pro- and anti-inflammatory actions of IL-6 signaling in monocytes in the 
synovial fluid.  
IL-6 upregulates the expression of M-CSFR on monocytes and induces the secretion of RANKL from 
synovial fibroblasts and T cells. Either M-CSF and RANKL or M-CSF and IL-6 lead to the 
differentiation of monocytes or macrophages to bone resorbing osteoclasts. M-CSF can further 
support the differentiation of monocytes to macrophages, which are potent producers of 
pro-inflammatory cytokines. The anti-inflammatory actions of IL-6 signaling in monocytes are 
exemplified by the secretion of IL-1Ra. IL-1β or other pro-inflammatory mediators may modulate the 
different actions of IL-6 by downregulation of the IL-6 receptor. 
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5 OUTLOOK 
This study has contributed to a better understanding of the regulation of gp130 surface 
expression, but questions remain unanswered and new questions have been raised by the 
results presented. 
In future experiments it would be interesting to investigate the extent to which crosstalk 
regulation of IL-6 signaling is translated to the level of gene expression. Induction of 
p-STAT3 target genes could be determined by quantitative RT-PCR after IL-6 stimulation 
with or without IL-1β pre-incubation. This analysis could additionally be performed with SF 
instead of IL-1β to further elucidate the role of gp130-mediated signals in JIA.  
In gp130 transgenic mice crosstalk should be investigated in other cell types and with 
different stimuli to explore whether the observed tendencies then become more apparent. 
Restriction of IL-6 signaling in murine macrophages by TNF-α and LPS has been shown 
before (Kiu et al., 2007). On the basis of these results it would be interesting to study 
crosstalk regulation in the two transgenic mouse strains in macrophages and to compare the 
impact of IL-1β to other pro-inflammatory stimuli.  
Since T cells of gp130-mut splenocytes showed an enhanced capacity to activate STAT3 in 
response to IL-6 in comparison to gp130-wt splenocytes (figure 3-13 B), it would be 
interesting to investigate differentiation of T cells derived from both strains towards the Th17 
lineage. Differentiation of Th17 cells depends on IL-6 and TGF-β. A possibly increased 
potential to differentiate into Th17 cells might be of importance for models of inflammation. 
Th17 cells are known to be involved in RA and other inflammatory conditions. 
In future, a model of arthritis and DSS colitis in transgenic mice will be used to further explore 
the impact of crosstalk regulation in chronic inflammatory conditions. Results from JIA 
patients and in vitro stimulation of PBMCs with SF (3.3.2.1) strongly suggest that crosstalk 
mechanisms may be of relevance in the inflamed joint. Furthermore, the differential 
regulation of gp130 expression and STAT3 phosphorylation in monocytes from IBD patients 
(figure 3-17 and figure 3-18) and CD11b+ cells from wt mice with chronic DSS colitis (figure 
3-21) provide evidence that regulation of gp130 surface expression is of relevance in the 
disease. Since CD11b is not an exclusive marker of monocytes, it will be necessary to 
discriminate between monocytes and other myeloid cells such as neutrophils in future 
experiments.  
It would also be interesting to include adult IBD patients in future analyses to investigate 
potential differences between adult and pediatric forms of IBD in terms of gp130 and 
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p-STAT3 expression. This idea is supported by the fact that Musso et al. did not discover 
increased p-STAT3 levels in PBMCs of adult IBD patients, which is in contrast to the results 
shown in this study and the one of Carey et al. (Carey et al., 2008; Musso et al., 2005). To 
support the hypothesis that increased STAT3 phosphorylation in monocytes from IBD 
patients arises from elevated gp130 expression and high levels of IL-6 and/or sIL-6R-IL-6 
complexes, IL-6 responsiveness should be investigated as in the experiments performed with 
PB and SF monocytes from JIA patients (figure 3-26 B). Furthermore, it would be interesting 
to elucidate the mechanism by which infliximab influences gp130 surface expression and 
STAT3 activation. The observed parallels in the murine system also provide a basis for the 
study of potential effects of infliximab in the mouse. It would be of further interest to isolate 
lamina propria cells in the final stages of chronic DSS colitis and to investigate gp130 surface 
expression and STAT3 phosphorylation in these cells. As with the changed gp130 
expression on SF monocytes compared to PB monocytes in JIA patients, it seems 
conceivable that similar mechanisms are present at the site of inflammation in IBD.  
Further experiments with PBMCs stimulated with SF should elucidate mechanisms of gp130 
downregulation in more detail. Phosphorylation of p38 and serine 782, for example, can be 
determined in monocytes after stimulation with SF. The anti-IL-6R antibody tocilizumab can 
be used to evaluate the impact on ligand-induced internalization of gp130 and IL-6R. 
Furthermore, the reason for increased levels of STAT3 phosphorylation in SF monocytes 
compared to PB monocytes (figure 3-26 A) will be investigated. Concretely, PBMCs will be 
stimulated with SF after pre-incubation of different blocking antibodies. By inhibition of 
protein synthesis, the extent to which SOCS3 contributes to the unresponsiveness of 
monocytes to IL-6 after pre-stimulation with SF (figure 3-27 A) could also be determined. 
Future analyses of gp130 regulation and associated changes will contribute to a better 
understanding of the sometimes contradictory effects of IL-6 in inflammatory conditions. 
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